(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁷: C07D 487/04, 519/00, A61K 31/5517, A61P 35/00

(21) International Application Number:
PCT/GB2005/000767

(22) International Filing Date: 1 March 2005 (01.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0404578.7   1 March 2004 (01.03.2004)   GB

(71) Applicant (for all designated States except US): SPIROGEN LIMITED [GB/GB]; 79 George Street, Ryde Isle of Wight PO33 2JF (GB).

(72) Inventors; and
(75) Inventors/Applicants (for US only): HOWARD, Philip Wilson [GB/GB]; 3 Westbourne Mews, The Maltings, St Albans Hertfordshire AL1 1LS (GB). GREGSON, Stephen John [GB/GB]; 6 Warepoint Drive, Thamesmead, London Greater London SE28 OHJ (GB). TIBERGHIEN, Arnaud Charles [FR/GB]; 36 Albert Westcott House, London Greater London SE17 3SE (GB).

(74) Agents: WATSON, Robert et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
—   with international search report

For two-letter codes and other abbreviations, refer to the "Guid-ance Notes on Codes and Abbreviations" appearing at the begin-ning of each regular issue of the PCT Gazette.

(54) Title: C/8/C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO'2,1-C!'1,4!BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

(57) Abstract: Compounds of formula (I): PBD-A-Y-X- $(Het)_{na}$-L- $(Het)_{nb}$-L- $(Het)_{nc}$-T- $(Het')_{nd}$-L- $(Het')_{ne}$-L- $(Het')_{nf}$-X' -Y' -A' -PBD' and salts, solvates and chemically protected forms thereof, are disclosed wherein the PBD units have the formulae (PBD) (PBD') with the bonds at the 8 position on each molecule bond to the A and A' groups respectively ; A is selected from O, S, NH or a single bond , and each Het and Het' is respectively an amino-heteroarylene-carbonyl group ; X and X' are both either NH or C (=O) -Q-C (=O) - wherein Q is a divalent group such that HY = R ; in a second aspectm the invention comprises compounds of the general formula (II) : PBD-A-Y-X-$(Het)_{ng}$-[L-$(Het)_{nh}$] $_{nj}$-X' -Y' -A' -PBD'. Wherein : PBD and PBD' are as defined above, X and X' are either NH and C(=O) respectively or C(O) and NH respectively ; the other substituents are defined in the claims. Further aspects of the present invention relate to their use in the manufacture of a medicament for the treatment of a proliferative disease.

C/8/C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO'2,1-C!'1,4!BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention relates to pyrrolobenzodiazepines (PBDs) and in particular to PBD dimers and methods of synthesising PBD

5   dimers.

Background to the invention
The inventors have previously disclosed in WO 00/12508 PBD dimers which are PBD monomers joined at the 8- positions by a

10   dioxyalkylene chain. These molecules exhibit a high level of cytotoxicity which arises due to the cross-linking of the two strands of DNA.

The inventors have also previously disclosed in WO 00/12506 the

15   use of amino acids attached to a PBD monomer to attempt sequence selective binding of the molecule in the minor groove of DNA.

It has also been disclosed in the prior art that certain heterocylic amino acids can be used in the synthesis of hairpin

20   polyamides which show some level of sequence selective interaction with DNA.

Disclosure of the invention
The present inventors have developed a series of PBD dimer

25   compounds with the chain linking the PBD monomer units comprising one or more amino-heteroarylene-carbonyl group.

In a first aspect, the invention comprises compounds of the general formula I:

30

PBD-A-Y-X-(Het)$_{na}$-L-(Het)$_{nb}$-L-(Het)$_{nc}$-T-(Het')$_{nd}$-L-(Het')$_{ne}$-L-(Het')$_{nf}$-X'-Y'-A'-PBD'

wherein:

2

PBD   PBD'

with the bonds at the 8 position on each molecule bond to the A
and A' groups respectively.

the dotted lines indicate the optional presence of a double bond

5   between C1 and C2 or C2 and C3;

R^2 and R^3 are independently selected from $-H$, $-OH$, $=O$, $=CH_2$, $-CN$,
$-R$, OR, halo, $=CH-R$, $O-SO_2-R$, CO_2R and COR;

R^6, R^7 and R^9 are independently selected from H, R, OH, OR, SH,
SR, NH_2, NHR, NRR', nitro, Me_3Sn and halo;

10   where R and R' are independently selected from optionally
substituted C_{1-7} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups; or
R^6 and R^7 together form a group $-O-(CH_2)_p-O-$, where p is 1 or 2;

R^{10} is a nitrogen protecting group and R^{15} is either $O-R^{11}$, wherein
R^{11} is a hydroxyl protecting group, or R^{15} is OH, $=O$ or $=S$,

15   preferably a hydroxyl protecting group or OH, or R^{10} and R^{15}
together form a double bond between C10 and N11;

A is selected from O, S, NH or a single bond;

Y is a divalent group such that HY = R, or a single bond;

X and X' are both either NH or C(=O);

20   each Het and Het' is independently an amino-heteroarylene-
carbonyl group;

each L is independently selected from β-alanine, glycine, 4-
aminobutanoic acid and a single bond;

T is a divalent linker group of the form:

25        $-NH-Q-NH-$ or $-C(=O)-Q-C(=O)-$

wherein Q is a divalent group such that HQ = R;

A', Y', Het', $R^{2'}$, $R^{3'}$, $R^{6'}$, $R^{7'}$, $R^{9'}$, $R^{10'}$, $R^{11'}$, R^{15} and $R^{15'}$ are all
independently selected from the same lists as previously defined
for A, Y, Het, R^2, R^3, R^6, R^7, R^9, R^{10}, R^{11} and R^{15} respectively;

na, nb, nc, nd, ne and nf are each independently 0 to 5 and the sum na + nb + nc + nd + ne + nf is 0 to 16.

In a second aspect, the invention comprises compounds of the general formula **II**:

PBD-A-Y-X-(Het)$_{ng}$-[L-(Het)$_{nh}$]$_{nj}$-X′-Y′-A′-PBD′

Wherein:

PBD   PBD'

with the bonds at the 8 position on PBD and PBD′ bonding to the A and A′ groups respectively.

A, A′, Y, Y′, Het, L, R^2, $R^{2'}$, R^3, $R^{3'}$, R^6, $R^{6'}$, R^7, $R^{7'}$, R^9, $R^{9'}$, R^{10}, $R^{10'}$, R^{11}, $R^{11'}$, R^{15} and $R^{15'}$ are as previously defined;

ng is 1 to 5, nh is 1 to 5 and nj is 0 to 3

X and X′ are either NH and C(=O) respectively or C(=O) and NH respectively.

In a third aspect, the invention comprises a method of synthesis of the dimers of formula **I** or **II**.

Further aspects of the present invention relate to compounds of formula **I** or **II** (including solvates thereof when R^{10} and R^{15} form a double bond between N10 and C11, and pharmaceutical salts thereof), their use in methods of therapy (particularly in treating proliferative diseases), pharmaceutical compositions comprising these, and their use in the manufacture of a medicament for the treatment of a proliferative disease.

Definitions

4

The Het amino-heteroarylene-carbonyl group

The Het amino-heteroarylene-carbonyl group is of the general
form:

   -J-G-J'-

5 and the Het' amino-heteroarylene-carbonyl group is of the general
form:

   -J'-G-J-

wherein J and J' are either NH and C(=O) respectively or C(=O)
and NH respectively and where when X is C(=O), J is NH and when X

10 is NH, J is C(=O);

G is an optionally substituted heteroarylene group, preferably a
C_{5-16} heteroarylene group, more preferably a C_{5-10} heteroarylene
group and even more preferably a C_{5-6} heteroarylene group.

15 Furthermore in a preferred embodiment, the G group is a five
membered heteroaryl group.

The heteroarylene group (G) may contain one or more heteroatoms
and preferably contains one heteroatom. The one or more

20 heteroatoms in the heteroarylene group (G) are independently
chosen from N, O and S and are preferably N.

The heteroarylene group (G) is optionally substituted with one or
more R groups. In a preferred embodiment the G group is

25 substituted at one or more of the heteroatom positions with at
least one R group, most preferably the R group is a methyl or
ethyl group.

The J and J' groups may be attached to the heteroarylene group

30 (G) at any of the heteroarylene atoms, preferably the J and J'
groups are attached to the G group at two separate carbon atoms
in the heteroarylene ring.

Where the G group is a six membered heteroarylene group, the J

35 and J' groups are preferably attached at the 2,6, 2,5, 3,6 or 3,5
positions.

5

Where the G group is a five membered heteroarylene group, the J
and J' groups are preferably attached at the 2,5, 2,4 or 3,5
positions.

Where the G group comprises two fused rings, the J and J' groups
are preferably attached to different rings.

Nitrogen protecting groups

Nitrogen protecting groups are well known in the art. Preferred
nitrogen protecting groups are carbamate protecting groups that
have the general formula:

$$R'^{10}\!\!-\!\!O\underset{*}{\overset{O}{\diagup\!\!\diagdown}}O$$

A large number of possible carbamate nitrogen protecting groups
are listed on pages 503 to 549 of Greene, T.W. and Wuts, G.M.,
Protective Groups in Organic Synthesis, 3rd Edition, John Wiley &
Sons, Inc., 1999, which is incorporated herein by reference.

Particularly preferred protecting groups include Alloc, Troc,
Teoc, BOC, Doc, Hoc, TcBOC, Fmoc, 1-Adoc and 2-Adoc.

Also suitable for use in the present invention are nitrogen
protecting groups which can be removed *in vivo* (e.g.
enzymatically, using light) as described in WO 00/12507, which is
incorporated herein by reference. Examples of these protecting
groups include:

, which is nitroreductase labile (e.g. using
ADEPT/GDEPT);

  and   , which are photolabile; and

which is glutathione labile (e.g. using NPEPT).

Oxygen protecting groups

Oxygen protecting groups are well known in the art. A large number of suitable groups are described on pages 23 to 200 of Greene, T.W. and Wuts, G.M., Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, Inc., 1999, which is incorporated herein by reference.

Classes of particular interest include silyl ethers, methyl ethers, alkyl ethers, benzyl ethers, esters, benzoates, carbonates, and sulfonates.

Heteroarylene: The term heteroarylene, as used herein, pertains to a divalent moiety obtained by removing two hydrogen atoms from aromatic ring atoms of a heteroaromatic compound. Heteroarylene compounds as described herein correspond to heteroaryl groups as defined below with one fewer hydrogen atoms on the ring atoms. In addition, the heteroarylene groups as defined herein may be optionally substituted.

Substituents

The phrase "optionally substituted" as used herein, pertains to a parent group which may be unsubstituted or which may be substituted.

Unless otherwise specified, the term "substituted" as used herein, pertains to a parent group which bears one or more substitutents. The term "substituent" is used herein in the conventional sense and refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent group. A wide variety of substituents are well known, and

7

methods for their formation and introduction into a variety of parent groups are also well known.

Examples of substituents are described in more detail below.

C_{1-7} alkyl: The term "C_{1-7} alkyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 7 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the sub-classes alkenyl, alkynyl, cycloalkyl, etc., discussed below.

Examples of saturated alkyl groups include, but are not limited to, methyl (C_1), ethyl (C_2), propyl (C_3), butyl (C_4), pentyl (C_5), hexyl (C_6) and heptyl (C_7).

Examples of saturated linear alkyl groups include, but are not limited to, methyl (C_1), ethyl (C_2), n-propyl (C_3), n-butyl (C_4), n-pentyl (amyl) (C_5), n-hexyl (C_6) and n-heptyl (C_7).

Examples of saturated branched alkyl groups include iso-propyl (C_3), iso-butyl (C_4), sec-butyl (C_4), tert-butyl (C_4), iso-pentyl (C_5), and neo-pentyl (C_5).

C_{2-7} Alkenyl: The term "C_{2-7} alkenyl" as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds.

Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, $-CH=CH_2$), 1-propenyl ($-CH=CH-CH_3$), 2-propenyl (allyl, $-CH-CH=CH_2$), isopropenyl (1-methylvinyl, $-C(CH_3)=CH_2$), butenyl (C_4), pentenyl (C_5), and hexenyl (C_6).

C_{2-7} alkynyl: The term "C_{2-7} alkynyl" as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds.

8

Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, $-C\equiv CH$) and 2-propynyl (propargyl, $-CH_2-C\equiv CH$).

5   C_{3-7} cycloalkyl: The term "C_{3-7} cycloalkyl" as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a cyclic hydrocarbon (carbocyclic) compound, which moiety has from 3 to 7 carbon atoms, including

10   from 3 to 7 ring atoms.

Examples of cycloalkyl groups include, but are not limited to, those derived from:
       saturated monocyclic hydrocarbon compounds:

15   cyclopropane (C_3), cyclobutane (C_4), cyclopentane (C_5), cyclohexane (C_6), cycloheptane (C_7), methylcyclopropane (C_4), dimethylcyclopropane (C_5), methylcyclobutane (C_5), dimethylcyclobutane (C_6), methylcyclopentane (C_6), dimethylcyclopentane (C_7) and methylcyclohexane (C_7);

20   unsaturated monocyclic hydrocarbon compounds: cyclopropene (C_3), cyclobutene (C_4), cyclopentene (C_5), cyclohexene (C_6), methylcyclopropene (C_4), dimethylcyclopropene (C_5), methylcyclobutene (C_5), dimethylcyclobutene (C_6), methylcyclopentene (C_6), dimethylcyclopentene (C_7) and

25   methylcyclohexene (C_7); and
            saturated polycyclic hydrocarbon compounds: norcarane (C_7), norpinane (C_7), norbornane (C_7).

       C_{3-20} heterocyclyl: The term "C_{3-20} heterocyclyl" as used herein,
30   pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms, of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.

35

In this context, the prefixes (e.g. C_{3-20}, C_{3-7}, C_{5-6}, etc.) denote the number of ring atoms, or range of number of ring atoms,

9

whether carbon atoms or heteroatoms. For example, the term
"C_{5-6}heterocyclyl", as used herein, pertains to a heterocyclyl
group having 5 or 6 ring atoms.

5   Examples of monocyclic heterocyclyl groups include, but are not
limited to, those derived from:
N_1: aziridine (C_3), azetidine (C_4), pyrrolidine
(tetrahydropyrrole) (C_5), pyrroline (e.g., 3-pyrroline,
2,5-dihydropyrrole) (C_5), 2H-pyrrole or 3H-pyrrole (isopyrrole,
10   isoazole) (C_5), piperidine (C_6), dihydropyridine (C_6),
tetrahydropyridine (C_6), azepine (C_7);
O_1: oxirane (C_3), oxetane (C_4), oxolane (tetrahydrofuran) (C_5),
oxole (dihydrofuran) (C_5), oxane (tetrahydropyran) (C_6),
dihydropyran (C_6), pyran (C_6), oxepin (C_7);
15   S_1: thiirane (C_3), thietane (C_4), thiolane (tetrahydrothiophene)
(C_5), thiane (tetrahydrothiopyran) (C_6), thiepane (C_7);
O_2: dioxolane (C_5), dioxane (C_6), and dioxepane (C_7);
O_3: trioxane (C_6);
N_2: imidazolidine (C_5), pyrazolidine (diazolidine) (C_5),
20   imidazoline (C_5), pyrazoline (dihydropyrazole) (C_5), piperazine
(C_6);
N_1O_1: tetrahydrooxazole (C_5), dihydrooxazole (C_5),
tetrahydroisoxazole (C_5), dihydroisoxazole (C_5), morpholine (C_6),
tetrahydrooxazine (C_6), dihydrooxazine (C_6), oxazine (C_6);
25   N_1S_1: thiazoline (C_5), thiazolidine (C_5), thiomorpholine (C_6);
N_2O_1: oxadiazine (C_6);
O_1S_1: oxathiole (C_5) and oxathiane (thioxane) (C_6); and,
$N_1O_1S_1$: oxathiazine (C_6).

30   Examples of substituted monocyclic heterocyclyl groups include
those derived from saccharides, in cyclic form, for example,
furanoses (C_5), such as arabinofuranose, lyxofuranose,
ribofuranose, and xylofuranse, and pyranoses (C_6), such as
allopyranose, altropyranose, glucopyranose, mannopyranose,
35   gulopyranose, idopyranose, galactopyranose, and talopyranose.

C_{5-20} aryl: The term "C_{5-20} aryl", as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 3 to 20 ring atoms. Preferably, each ring has from 5 to 7 ring
5   atoms.

In this context, the prefixes (e.g. C_{3-20}, C_{5-7}, C_{5-6}, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C_{5-6}
10   aryl" as used herein, pertains to an aryl group having 5 or 6 ring atoms.

The ring atoms may be all carbon atoms, as in "carboaryl groups". Examples of carboaryl groups include, but are not limited to,
15   those derived from benzene (i.e. phenyl) (C_6), naphthalene (C_{10}), azulene (C_{10}), anthracene (C_{14}), phenanthrene (C_{14}), naphthacene (C_{18}), and pyrene (C_{16}).

Examples of aryl groups which comprise fused rings, at least one
20   of which is an aromatic ring, include, but are not limited to, groups derived from indane (e.g. 2,3-dihydro-1H-indene) (C_9), indene (C_9), isoindene (C_9), tetraline (1,2,3,4-tetrahydronaphthalene (C_{10}), acenaphthene (C_{12}), fluorene (C_{13}), phenalene (C_{13}), acephenanthrene (C_{15}), and aceanthrene
25   (C_{16}).

Alternatively, the ring atoms may include one or more heteroatoms, as in "heteroaryl groups". Examples of monocyclic heteroaryl groups include, but are not limited to, those derived
30   from:
N_1: pyrrole (azole) (C_5), pyridine (azine) (C_6);
O_1: furan (oxole) (C_5);
S_1: thiophene (thiole) (C_5);
N_1O_1: oxazole (C_5), isoxazole (C_5), isoxazine (C_6);
35   N_2O_1: oxadiazole (furazan) (C_5);
N_3O_1: oxatriazole (C_5);
N_1S_1: thiazole (C_5), isothiazole (C_5);

11

N_2: imidazole (1,3-diazole) (C_5), pyrazole (1,2-diazole) (C_5), pyridazine (1,2-diazine) (C_6), pyrimidine (1,3-diazine) (C_6) (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C_6);

N_3: triazole (C_5), triazine (C_6); and,

5   N_4: tetrazole (C_5).

Examples of heteroaryl which comprise fused rings, include, but are not limited to:

C_9 (with 2 fused rings) derived from benzofuran (O_1),

10   isobenzofuran (O_1), indole (N_1), isoindole (N_1), indolizine (N_1), indoline (N_1), isoindoline (N_1), purine (N_4) (e.g., adenine, guanine), benzimidazole (N_2), indazole (N_2), benzoxazole (N_1O_1), benzisoxazole (N_1O_1), benzodioxole (O_2), benzofurazan (N_2O_1), benzotriazole (N_3), benzothiofuran (S_1), benzothiazole (N_1S_1),

15   benzothiadiazole (N_2S);

C_{10} (with 2 fused rings) derived from chromene (O_1), isochromene (O_1), chroman (O_1), isochroman (O_1), benzodioxan (O_2), quinoline (N_1), isoquinoline (N_1), quinolizine (N_1), benzoxazine (N_1O_1), benzodiazine (N_2), pyridopyridine (N_2), quinoxaline (N_2),

20   quinazoline (N_2), cinnoline (N_2), phthalazine (N_2), naphthyridine (N_2), pteridine (N_4);

C_{11} (with 2 fused rings) derived from benzodiazepine (N_2);

C_{13} (with 3 fused rings) derived from carbazole (N_1), dibenzofuran (O_1), dibenzothiophene (S_1), carboline (N_2),

25   perimidine (N_2), pyridoindole (N_2); and,

C_{14} (with 3 fused rings) derived from acridine (N_1), xanthene (O_1), thioxanthene (S_1), oxanthrene (O_2), phenoxathiin (O_1S_1), phenazine (N_2), phenoxazine (N_1O_1), phenothiazine (N_1S_1), thianthrene (S_2), phenanthridine (N_1), phenanthroline (N_2),

30   phenazine (N_2).

The above groups, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed

35   below.

Halo: -F, -Cl, -Br, and -I.

12

Hydroxy: -OH.

Ether: -OR, wherein R is an ether substituent, for example, a C_{1-7}
5   alkyl group (also referred to as a C_{1-7} alkoxy group, discussed
below), a C_{3-20} heterocyclyl group (also referred to as a C_{3-20}
heterocyclyloxy group), or a C_{5-20} aryl group (also referred to as
a C_{5-20} aryloxy group), preferably a C_{1-7}alkyl group.

10   Alkoxy: -OR, wherein R is an alkyl group, for example, a C_{1-7}
alkyl group. Examples of C_{1-7} alkoxy groups include, but are not
limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -
O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy),
-O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).

15
Acetal: -CH(OR^1)(OR^2), wherein R^1 and R^2 are independently acetal
substituents, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl
group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group, or, in
the case of a "cyclic" acetal group, R^1 and R^2, taken together
20   with the two oxygen atoms to which they are attached, and the
carbon atoms to which they are attached, form a heterocyclic ring
having from 4 to 8 ring atoms. Examples of acetal groups
include, but are not limited to, -CH(OMe)$_2$, -CH(OEt)$_2$, and
-CH(OMe)(OEt).

25
Hemiacetal: -CH(OH)(OR^1), wherein R^1 is a hemiacetal substituent,
for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a
C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of
hemiacetal groups include, but are not limited to, -CH(OH)(OMe)
30   and -CH(OH)(OEt).

Ketal: -CR(OR^1)(OR^2), where R^1 and R^2 are as defined for acetals,
and R is a ketal substituent other than hydrogen, for example, a
C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group,
35   preferably a C_{1-7} alkyl group. Examples ketal groups include, but
are not limited to, -C(Me)(OMe)$_2$, -C(Me)(OEt)$_2$, -C(Me)(OMe)(OEt),
-C(Et)(OMe)$_2$, -C(Et)(OEt)$_2$, and -C(Et)(OMe)(OEt).

13

Hemiketal: $-CR(OH)(OR^1)$, where R^1 is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20}

5   aryl group, preferably a C_{1-7} alkyl group. Examples of hemiacetal groups include, but are not limited to, $-C(Me)(OH)(OMe)$, $-C(Et)(OH)(OMe)$, $-C(Me)(OH)(OEt)$, and $-C(Et)(OH)(OEt)$.

Oxo (keto, -one): $=O$.

10

Thione (thioketone): $=S$.

Imino (imine): $=NR$, wherein R is an imino substituent, for example, hydrogen, C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or

15 a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $=NH$, $=NMe$, $=NEt$, and $=NPh$.

Formyl (carbaldehyde, carboxaldehyde): $-C(=O)H$.

20

Acyl (keto): $-C(=O)R$, wherein R is an acyl substituent, for example, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylacyl or C_{1-7} alkanoyl), a C_{3-20} heterocyclyl group (also referred to as C_{3-20} heterocyclylacyl), or a C_{5-20} aryl group (also referred to as C_{5-20}

25 arylacyl), preferably a C_{1-7} alkyl group. Examples of acyl groups include, but are not limited to, $-C(=O)CH_3$ (acetyl), $-C(=O)CH_2CH_3$ (propionyl), $-C(=O)C(CH_3)_3$ (t-butyryl), and $-C(=O)Ph$ (benzoyl, phenone).

30 Carboxy (carboxylic acid): $-C(=O)OH$.

Thiocarboxy (thiocarboxylic acid): $-C(=S)SH$.

Thiolocarboxy (thiolocarboxylic acid): $-C(=O)SH$.

35

Thionocarboxy (thionocarboxylic acid): $-C(=S)OH$.

14

Imidic acid: -C(=NH)OH.

Hydroxamic acid: -C(=NOH)OH.

5   Ester (carboxylate, carboxylic acid ester, oxycarbonyl):
    -C(=O)OR, wherein R is an ester substituent, for example, a C_{1-7}
    alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group,
    preferably a C_{1-7} alkyl group. Examples of ester groups include,
    but are not limited to, -C(=O)OCH$_3$, -C(=O)OCH$_2$CH$_3$, -C(=O)OC(CH$_3$)$_3$,
10 and -C(=O)OPh.

    Acyloxy (reverse ester): -OC(=O)R, wherein R is an acyloxy
    substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl
    group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group.
15 Examples of acyloxy groups include, but are not limited to,
    -OC(=O)CH$_3$ (acetoxy), -OC(=O)CH$_2$CH$_3$, -OC(=O)C(CH$_3$)$_3$, -OC(=O)Ph, and
    -OC(=O)CH$_2$Ph.

    Oxycarboyloxy: -OC(=O)OR, wherein R is an ester substituent, for
20 example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20}
    aryl group, preferably a C_{1-7} alkyl group. Examples of ester
    groups include, but are not limited to, -OC(=O)OCH$_3$,
    -OC(=O)OCH$_2$CH$_3$, -OC(=O)OC(CH$_3$)$_3$, and -OC(=O)OPh.

25 Amino: -NR^{1}R^2, wherein R^1 and R^2 are independently amino
    substituents, for example, hydrogen, a C_{1-7} alkyl group (also
    referred to as C_{1-7} alkylamino or di-C_{1-7} alkylamino), a C_{3-20}
    heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7}
    alkyl group, or, in the case of a "cyclic" amino group, R^1 and R^2,
30 taken together with the nitrogen atom to which they are attached,
    form a heterocyclic ring having from 4 to 8 ring atoms. Amino
    groups may be primary (-NH$_2$), secondary (-NHR^1), or tertiary (-
    NHR^{1}R^2), and in cationic form, may be quaternary (-$^+$NR^{1}R^{2}R^3).
    Examples of amino groups include, but are not limited to, -NH$_2$,
35 -NHCH$_3$, -NHC(CH$_3$)$_2$, -N(CH$_3$)$_2$, -N(CH$_2$CH$_3$)$_2$, and -NHPh. Examples of
   cyclic amino groups include, but are not limited to, aziridino,

15

azetidino, pyrrolidino, piperidino, piperazino, morpholino, and
thiomorpholino.

Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide):
-C(=O)NR^{1}R^2, wherein R^1 and R^2 are independently amino
substituents, as defined for amino groups. Examples of amido
groups include, but are not limited to, -C(=O)NH$_2$, -C(=O)NHCH$_3$,
-C(=O)N(CH$_3$)$_2$, -C(=O)NHCH$_2$CH$_3$, and -C(=O)N(CH$_2$CH$_3$)$_2$, as well as
amido groups in which R^1 and R^2, together with the nitrogen atom
to which they are attached, form a heterocyclic structure as in,
for example, piperidinocarbonyl, morpholinocarbonyl,
thiomorpholinocarbonyl, and piperazinocarbonyl.

Thioamido (thiocarbamyl): -C(=S)NR^{1}R^2, wherein R^1 and R^2 are
independently amino substituents, as defined for amino groups.
Examples of amido groups include, but are not limited to,
-C(=S)NH$_2$, -C(=S)NHCH$_3$, -C(=S)N(CH$_3$)$_2$, and -C(=S)NHCH$_2$CH$_3$.

Acylamido (acylamino): -NR^{1}C(=O)R^2, wherein R^1 is an amide
substituent, for example, hydrogen, a C$_{1-7}$ alkyl group, a C$_{3-20}$
heterocyclyl group, or a C$_{5-20}$ aryl group, preferably hydrogen or a
C$_{1-7}$ alkyl group, and R^2 is an acyl substituent, for example, a C$_{1-7}$
alkyl group, a C$_{3-20}$ heterocyclyl group, or a C$_{5-20}$aryl group,
preferably hydrogen or a C$_{1-7}$ alkyl group. Examples of acylamide
groups include, but are not limited to, -NHC(=O)CH$_3$,
-NHC(=O)CH$_2$CH$_3$, and -NHC(=O)Ph. R^1 and R^2 may together form a
cyclic structure, as in, for example, succinimidyl, maleimidyl,
and phthalimidyl:

succinimidyl   maleimidyl   phthalimidyl

Aminocarbonyloxy: -OC(=O)NR^{1}R^2, wherein R^1 and R^2 are
independently amino substituents, as defined for amino groups.

16

Examples of aminocarbonyloxy groups include, but are not limited to, $-OC(=O)NH_2$, $-OC(=O)NHMe$, $-OC(=O)NMe_2$, and $-OC(=O)NEt_2$.

Ureido: $-N(R^1)CONR^2R^3$ wherein R^2 and R^3 are independently amino substituents, as defined for amino groups, and R^1 is a ureido substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ureido groups include, but are not limited to, $-NHCONH_2$, $-NHCONHMe$, $-NHCONHEt$, $-NHCONMe_2$, $-NHCONEt_2$, $-NMeCONH_2$, $-NMeCONHMe$, $-NMeCONHEt$, $-NMeCONMe_2$, and $-NMeCONEt_2$.

Guanidino: $-NH-C(=NH)NH_2$.

Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon atom,

Imino: $=NR$, wherein R is an imino substituent, for example, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group. Examples of imino groups include, but are not limited to, $=NH$, $=NMe$, and $=NEt$.

Amidine (amidino): $-C(=NR)NR_2$, wherein each R is an amidine substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group. Examples of amidine groups include, but are not limited to, $-C(=NH)NH_2$, $-C(=NH)NMe_2$, and $-C(=NMe)NMe_2$.

Nitro: $-NO_2$.

Nitroso: $-NO$.

Azido: $-N_3$.

Cyano (nitrile, carbonitrile): -CN.

Isocyano: -NC.

Cyanato: -OCN.

Isocyanato: -NCO.

Thiocyano (thiocyanato): -SCN.

Isothiocyano (isothiocyanato): -NCS.

Sulfhydryl (thiol, mercapto): -SH.

Thioether (sulfide): -SR, wherein R is a thioether substituent, for example, a C_{1-7} alkyl group (also referred to as a C_{1-7}alkylthio group), a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of C_{1-7} alkylthio groups include, but are not limited to, $-SCH_3$ and $-SCH_2CH_3$.

Disulfide: -SS-R, wherein R is a disulfide substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group (also referred to herein as C_{1-7} alkyl disulfide). Examples of C_{1-7} alkyl disulfide groups include, but are not limited to, $-SSCH_3$ and $-SSCH_2CH_3$.

Sulfine (sulfinyl, sulfoxide): -S(=O)R, wherein R is a sulfine substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfine groups include, but are not limited to, $-S(=O)CH_3$ and $-S(=O)CH_2CH_3$.

Sulfone (sulfonyl): $-S(=O)_2R$, wherein R is a sulfone substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group, including, for example, a fluorinated or perfluorinated C_{1-7} alkyl group. Examples of sulfone groups include, but are not limited to,

18

$-S(=O)_2CH_3$ (methanesulfonyl, mesyl), $-S(=O)_2CF_3$ (triflyl),
$-S(=O)_2CH_2CH_3$ (esyl), $-S(=O)_2C_4F_9$ (nonaflyl), $-S(=O)_2CH_2CF_3$
(tresyl), $-S(=O)_2CH_2CH_2NH_2$ (tauryl), $-S(=O)_2Ph$ (phenylsulfonyl,
besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl
(closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl),
2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen-
1-ylsulfonate (dansyl).

Sulfinic acid (sulfino): $-S(=O)OH$, $-SO_2H$.

Sulfonic acid (sulfo): $-S(=O)_2OH$, $-SO_3H$.

Sulfinate (sulfinic acid ester): $-S(=O)OR$; wherein R is a
sulfinate substituent, for example, a C_{1-7} alkyl group, a C_{3-20}
heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl
group. Examples of sulfinate groups include, but are not limited
to, $-S(=O)OCH_3$ (methoxysulfinyl; methyl sulfinate) and
$-S(=O)OCH_2CH_3$ (ethoxysulfinyl; ethyl sulfinate).

Sulfonate (sulfonic acid ester): $-S(=O)_2OR$, wherein R is a
sulfonate substituent, for example, a C_{1-7} alkyl group, a C_{3-20}
heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl
group. Examples of sulfonate groups include, but are not limited
to, $-S(=O)_2OCH_3$ (methoxysulfonyl; methyl sulfonate) and
$-S(=O)_2OCH_2CH_3$ (ethoxysulfonyl; ethyl sulfonate).

Sulfinyloxy: $-OS(=O)R$, wherein R is a sulfinyloxy substituent,
for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a
C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of
sulfinyloxy groups include, but are not limited to, $-OS(=O)CH_3$
and $-OS(=O)CH_2CH_3$.

Sulfonyloxy: $-OS(=O)_2R$, wherein R is a sulfonyloxy substituent,
for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a
C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of
sulfonyloxy groups include, but are not limited to, $-OS(=O)_2CH_3$
(mesylate) and $-OS(=O)_2CH_2CH_3$ (esylate).

19

Sulfate: $-OS(=O)_2OR$; wherein R is a sulfate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfate groups include, but are not limited to, $-OS(=O)_2OCH_3$ and $-SO(=O)_2OCH_2CH_3$.

Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide): $-S(=O)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, $-S(=O)NH_2$, $-S(=O)NH(CH_3)$, $-S(=O)N(CH_3)_2$, $-S(=O)NH(CH_2CH_3)$, $-S(=O)N(CH_2CH_3)_2$, and $-S(=O)NHPh$.

Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide): $-S(=O)_2NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfonamido groups include, but are not limited to, $-S(=O)_2NH_2$, $-S(=O)_2NH(CH_3)$, $-S(=O)_2N(CH_3)_2$, $-S(=O)_2NH(CH_2CH_3)$, $-S(=O)_2N(CH_2CH_3)_2$, and $-S(=O)_2NHPh$.

Sulfamino: $-NR^1S(=O)_2OH$, wherein R^1 is an amino substituent, as defined for amino groups. Examples of sulfamino groups include, but are not limited to, $-NHS(=O)_2OH$ and $-N(CH_3)S(=O)_2OH$.

Sulfonamino: $-NR^1S(=O)_2R$, wherein R^1 is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfonamino groups include, but are not limited to, $-NHS(=O)_2CH_3$ and $-N(CH_3)S(=O)_2C_6H_5$.

Sulfinamino: $-NR^1S(=O)R$, wherein R^1 is an amino substituent, as defined for amino groups, and R is a sulfinamino substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinamino groups include, but are not limited to, $-NHS(=O)CH_3$ and $-N(CH_3)S(=O)C_6H_5$.

Phosphino (phosphine): $-PR_2$, wherein R is a phosphino substituent, for example, $-H$, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably $-H$, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphino groups include, but are not limited to, $-PH_2$, $-P(CH_3)_2$, $-P(CH_2CH_3)_2$, $-P(t-Bu)_2$, and $-P(Ph)_2$.

Phospho: $-P(=O)_2$.

Phosphinyl (phosphine oxide): $-P(=O)R_2$, wherein R is a phosphinyl substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group or a C_{5-20} aryl group. Examples of phosphinyl groups include, but are not limited to, $-P(=O)(CH_3)_2$, $-P(=O)(CH_2CH_3)_2$, $-P(=O)(t-Bu)_2$, and $-P(=O)(Ph)_2$.

Phosphonic acid (phosphono): $-P(=O)(OH)_2$.

Phosphonate (phosphono ester): $-P(=O)(OR)_2$, where R is a phosphonate substituent, for example, $-H$, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably $-H$, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphonate groups include, but are not limited to, $-P(=O)(OCH_3)_2$, $-P(=O)(OCH_2CH_3)_2$, $-P(=O)(O-t-Bu)_2$, and $-P(=O)(OPh)_2$.

Phosphoric acid (phosphonooxy): $-OP(=O)(OH)_2$.

Phosphate (phosphonooxy ester): $-OP(=O)(OR)_2$, where R is a phosphate substituent, for example, $-H$, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably $-H$, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphate groups include, but are not limited to, $-OP(=O)(OCH_3)_2$, $-OP(=O)(OCH_2CH_3)_2$, $-OP(=O)(O-t-Bu)_2$, and $-OP(=O)(OPh)_2$.

Phosphorous acid: $-OP(OH)_2$.

21

Phosphite: $-OP(OR)_2$, where R is a phosphite substituent, for example, $-H$, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably $-H$, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphite groups include, but are not limited

5   to, $-OP(OCH_3)_2$, $-OP(OCH_2CH_3)_2$, $-OP(O-t-Bu)_2$, and $-OP(OPh)_2$.

Phosphoramidite: $-OP(OR^1)-NR^2_2$, where R^1 and R^2 are phosphoramidite substituents, for example, $-H$, a (optionally substituted) C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group,

10   preferably $-H$, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphoramidite groups include, but are not limited to, $-OP(OCH_2CH_3)-N(CH_3)_2$, $-OP(OCH_2CH_3)-N(i-Pr)_2$, and $-OP(OCH_2CH_2CN)-N(i-Pr)_2$.

15   Phosphoramidate: $-OP(=O)(OR^1)-NR^2_2$, where R^1 and R^2 are phosphoramidate substituents, for example, $-H$, a (optionally substituted) C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably $-H$, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphoramidate groups include, but are not

20   limited to, $-OP(=O)(OCH_2CH_3)-N(CH_3)_2$, $-OP(=O)(OCH_2CH_3)-N(i-Pr)_2$, and $-OP(=O)(OCH_2CH_2CN)-N(i-Pr)_2$.

Proliferative Diseases
One of ordinary skill in the art is readily able to determine

25   whether or not a candidate compound treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below.

30   The term "proliferative disease" pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether *in vitro* or *in vivo*.

35   Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g.

22

histocytoma, glioma, astrocyoma, osteoma), cancers (e.g. lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer,

5   bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis.

10   Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g. bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.

15   Methods of Treatment
     As described above, the present invention provide the use of a compound of formula I or II in a method of therapy. Preferably the compounds of formulae I or II comprise a N10-C11 imine bond, or the N10 is protected by a nitrogen protecting group (R^{10}) which

20   can be removed in vivo and the C11 substituent (R^{11}) is OH. Also provided is a method of treatment, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of formula I or II, preferably in the form of a pharmaceutical composition, which is the third aspect of the

25   present invention. The term "therapeutically effective amount" is an amount sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is

30   being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors.

     A compound may be administered alone or in combination with other

35   treatments, either simultaneously or sequentially dependent upon the condition to be treated. Examples of treatments and therapies include, but are not limited to, chemotherapy (the

23

administration of active agents, including, e.g. drugs; surgery; and radiation therapy. If the compound of formula **I** or **II** bears a carbamate-based nitrogen protecting group which may be removed *in vivo*, then the methods of treatment described in WO 00/12507

5   (ADEPT, GDEPT and PDT) may be used.

Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may comprise, in addition to the active ingredient, i.e. a compound

10 of formula **I** or **II**, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend

15 on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or intravenous.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a

20 solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or

25 polyethylene glycol may be included. A capsule may comprise a solid carrier such a gelatin.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will

30 be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated

35 Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Includes Other Forms

Unless otherwise specified, included in the above are the well
known ionic, salt, solvate, and protected forms of these
5   substituents. For example, a reference to carboxylic acid
(-COOH) also includes the anionic (carboxylate) form (-COO⁻), a
salt or solvate thereof, as well as conventional protected forms.
Similarly, a reference to an amino group includes the protonated
form (-N⁺HR¹R²), a salt or solvate of the amino group, for
10   example, a hydrochloride salt, as well as conventional protected
forms of an amino group. Similarly, a reference to a hydroxyl
group also includes the anionic form (-O⁻), a salt or solvate
thereof, as well as conventional protected forms.

15   Isomers, Salts and Solvates

Certain compounds may exist in one or more particular geometric,
optical, enantiomeric, diasteriomeric, epimeric, atropic,
stereoisomeric, tautomeric, conformational, or anomeric forms,
including but not limited to, cis- and trans-forms; E- and Z-
20   forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and
meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms;
keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal-
and anticlinal-forms; α- and β-forms; axial and equatorial forms;
boat-, chair-, twist-, envelope-, and halfchair-forms; and
25   combinations thereof, hereinafter collectively referred to as
"isomers" (or "isomeric forms").

Preferably compounds of the present invention have the following
stereochemistry at the C11 position:

30

Note that, except as discussed below for tautomeric forms,
specifically excluded from the term "isomers", as used herein,
are structural (or constitutional) isomers (i.e. isomers which

differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, $-OCH_3$, is not to be construed as a reference to its structural isomer, a hydroxymethyl group, $-CH_2OH$. Similarly, a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g. C_{1-7} alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).

The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hyroxyazo, and nitro/aci-nitro.

keto   enol   enolate

Note that specifically included in the term "isomer" are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including ^1H, ^2H (D), and ^3H (T); C may be in any isotopic form, including ^{12}C, ^{13}C, and ^{14}C; O may be in any isotopic form, including ^{16}O and ^{18}O; and the like.

Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.

Unless otherwise specified, a reference to a particular compound
also includes ionic, salt, solvate, and protected forms of
thereof, for example, as discussed below.

5   It may be convenient or desirable to prepare, purify, and/or
handle a corresponding salt of the active compound, for example,
a pharmaceutically-acceptable salt. Examples of pharmaceutically
acceptable salts are discussed in Berge, _et al._, _J. Pharm. Sci._,
66, 1-19 (1977).

10
For example, if the compound is anionic, or has a functional
group which may be anionic (e.g. -COOH may be -COO⁻), then a salt
may be formed with a suitable cation. Examples of suitable
inorganic cations include, but are not limited to, alkali metal
15   ions such as Na^+ and K^+, alkaline earth cations such as Ca^{2+} and
Mg^{2+}, and other cations such as Al^{3+}. Examples of suitable
organic cations include, but are not limited to, ammonium ion
(i.e. NH_4^+) and substituted ammonium ions (e.g. NH_3R^+, $NH_2R_2^+$,
NHR_3^+, NR_4^+). Examples of some suitable substituted ammonium ions
20   are those derived from: ethylamine, diethylamine,
dicyclohexylamine, triethylamine, butylamine, ethylenediamine,
ethanolamine, diethanolamine, piperazine, benzylamine,
phenylbenzylamine, choline, meglumine, and tromethamine, as well
as amino acids, such as lysine and arginine. An example of a
25   common quaternary ammonium ion is $N(CH_3)_4^+$.

If the compound is cationic, or has a functional group which may
be cationic (e.g. $-NH_2$ may be $-NH_3^+$), then a salt may be formed
with a suitable anion. Examples of suitable inorganic anions
30   include, but are not limited to, those derived from the following
inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric,
sulfurous, nitric, nitrous, phosphoric, and phosphorous.

Examples of suitable organic anions include, but are not limited
35   to, those derived from the following organic acids:
2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic,
camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic,

27

ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic,
glycolic, hydroxymaleic, hydroxynaphthalene carboxylic,
isethionic, lactic, lactobionic, lauric, maleic, malic,
methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic,
5   pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic,
salicylic, stearic, succinic, sulfanilic, tartaric,
toluenesulfonic, and valeric. Examples of suitable polymeric
organic anions include, but are not limited to, those derived
from the following polymeric acids: tannic acid, carboxymethyl
10 cellulose.

A particular salt form of interest can be formed from compounds
of formula **I** and **II,** where R^{10} and R^{15} form an imine bond, by
reacting said compound with a bisulphite salt to form a
15 bisulphite derivative of the PBD. The PBD moieties of these
compounds can be represented as:

PBD   PBD'

where M and M′ are independently monovalent pharmaceutically
acceptable cations, or together form a divalent pharmaceutically
20 acceptable cation, and the other groups are as previously
defined.

It may be convenient or desirable to prepare, purify, and/or
handle a corresponding solvate of the active compound. The term
25 "solvate" is used herein in the conventional sense to refer to a
complex of solute (e.g. active compound, salt of active compound)
and solvent. If the solvent is water, the solvate may be
conveniently referred to as a hydrate, for example, a mono-
hydrate, a di-hydrate, a tri-hydrate, etc.

30
Solvates of particular relevance to the present invention are
those where the solvent adds across the imine bond of the PBD

28

moiety, which is illustrated below where the solvent is water or
an alcohol (R^AOH, where R^A is an ether substituent as described
above):

5   These forms can be called the carbinolamine and carbinolamine
ether forms of the PBD. The balance of these equilibria depend
on the conditions in which the compounds are found, as well as
the nature of the moiety itself.

10 In general any nucleophilic solvent is capable of forming such
solvates as illustrated above for hydroxylic solvents. Other
nucleophilic solvents include thiols and amines.

These solvates may be isolated in solid form, for example, by
15 lyophilisation.

General synthetic routes
For a general discussion of the synthetic routes used to obtain
compounds of formulae **I** and **II**, the formulae **I** and **II** can each be
20 conveniently divided into two capping groups joined by a linker
group. The capping groups comprise the units PBD-A-Y-X- and
-X'-Y'-A'-PBD' and the linker groups comprise:
        -(Het)$_{na}$-L-(Het)$_{nb}$-L-(Het)$_{nc}$-T-(Het')$_{nd}$-L-(Het')$_{ne}$-L-(Het')$_{nf}$-
in the case of formula **I** and:
25   -(Het)$_{ng}$-[L-(Het)$_{nh}$]$_{nj}$-
in the case of formula **II**.

A key step in the synthesis of compounds of formula **I** or **II** is
the linking of two capping groups with a linker group. In
30 general the capping group may be joined to the linking group by a
peptide bond of the form -NH-C(=O)-. This can be formed either
by an amine terminated capping group reacting with a carboxylic
acid (or equivalent) terminated linking group or vice versa

(carboxylic acid (or equivalent) terminated capping group with an amine terminated linking group).

Reaction of an amine terminated capping group with a carboxylic
5   *acid (or equivalent) terminated linking group*

10   *Scheme 1*

The generalised scheme 1 illustrates two possible methods for coupling an amine terminated capping group with a carboxylic acid (or equivalent) terminated linking group. In this scheme, only a
15   mono-acidic linker compound **III** is shown. The linker group may contain additional functional groups or protected functional groups which may take part in further reactions of the product **VII**. It is also envisaged that the linker compound **III** may be a diacid. This would lead to a diacid chloride analogue of
20   compound **IV** and ultimately to a product **VII** containing two capping groups joined by one linker group.

The first method proceeds by formation of the acid chloride (**IV**) of the carboxylic acid terminated linking compound (**III**). This
25   may be achieved by reaction of **III** with oxalyl chloride. Compound **IV** is then reacted with the amine terminated capping group (**V**) in an elimination reaction to form a peptide bond.

Scheme 1 shows the coupling reaction proceeding *via* the acid chloride **IV** however it is envisaged that any activated carboxylic acid analogue of compound **IV** known in the art may alternatively

5   be used in the coupling reaction.

The second coupling method proceeds without activation of the acid linking compound **III**. Instead the peptide coupling reaction proceeds directly with the amine terminated capping group in the

10   presence of a coupling initiator. Preferred peptide coupling initiators may be chosen from BOP, BOP-Cl, DCC, DIC, FDPP, HATU, HOBt, PyBroP and TBTU. Preferably the coupling initiator is HOBt more preferably HOBt in conjunction with EDCI (as shown in scheme 1).

15

In both methods, the N10 position of the PBD group in the capping group (**V**) is preferably protected during the coupling reaction to avoid any unwanted side reactions. The group Prot-PBD is used to indicate that the N10 position on the PBD molecule is protected.

20   Following the coupling reaction, the N10 protection on the PBD group in the capping group may be removed to yield the unprotected PBD dimer coupled to a linker unit (**VII**).

Furthermore, in the Prot-PBD group, the C11 hydroxyl group may

25   optionally be protected during the coupling reaction. This may be achieved by using any hydroxyl protecting group known in the art, however, the C11 hydroxyl protecting group is preferably THP or a silyl ether (for example TBS).

30   The imine bond in the compound VI can be deprotected by standard methods to yield the unprotected compound (which may be in its carbinolamine or carbinolamine ether form , depending on the solvents used). For example if R^{10} in formula **I** or **II** is Alloc, then the preferred method of deprotection is hydrogenation using

35   palladium on carbon to remove the N10 protecting group, followed by the elimination of water. If R^{10} is Troc, then the

31

deprotection is carried out using a Cd/Pb couple to yield the compound VII.

Reaction of a carboxylic acid (or equivalent) terminated capping group with an amine terminated linking group

Scheme 2

The generalised scheme 2 illustrates two possible methods for coupling a carboxylic acid (or equivalent) terminated capping group with an amine terminated linking group. In this scheme, only a mono-amine linker group **X** is shown. The linker group may contain additional functional groups or protected functional groups which may take part in further reactions of the product **XII**. It is also envisaged that the linker compound **X** may be a diamine. This would lead to a product **XII** containing two capping groups joined by one linker group.

Conditions for the coupling reactions in scheme 2 are as for those shown in scheme 1. It is important however that when the capping group **VIII** is carboxylic acid (or equivalent) terminated, the PBD group in compound **VIII** is protected at both the N10 and C11 positions. This is to avoid unwanted side reactions resulting in products other than compound **XII**. The group Prot'-PBD is used to indicate that the N10 and C11 positions of the PBD

molecule are protected.   The N10 nitrogen protecting group (R^{10})
may be any nitrogen protecting group known in the art and is
preferably a carbamate protecting group and is more preferably
Alloc, Troc, Fmoc or Boc.   The C11 oxygen protecting group may be

5   any oxygen protecting group known in the art and is preferably
THP or TBS.

Deprotection of compound **XI** at both the N10 and C11 positions
(nitrogen and oxygen protection respectively) is achieved by

10   methods known in the art.

In both scheme 1 and 2, if the nitrogen protecting group (R^{10}) is
such that the desired end product still contains it, e.g. if it
is removable *in vivo*, then the C11 unprotected forms of compounds

15   **VII** or **XII** above may be synthesised by removal of the oxygen
protecting groups under suitable conditions to leave the R^{10} group
unaffected.

Synthesis of amine terminated capping groups

20   As indicated above, the capping groups at each end of the linker
chain may terminate either in an amine group or a carboxylic acid
group (or equivalent).   This allows coupling to a linker chain
terminating in either an acid group or an amine group
respectively by the methods shown above.   Synthesis of an amine

25   terminated capping group is shown generally in scheme 3:

33

Scheme 3

5   The starting material **XIII** (hydroxyl-5-substituted-2-nitro-
       benzaldehyde) may be coupled under Mitsunobu conditions, using,
       for example, PPh₃, to an N-protected hydroxy-amide (**XIV**).
       Subsequent oxidation of the aldehyde gives the corresponding acid
       (**XV**). The R⁷ group is as defined above but is preferably not
10   reactive under Mitsunobu conditions nor susceptible to oxidation.
       The oxidation conditions used are known in the art but the
       reaction is preferably performed using hot aqueous KMnO₄.

       The protected amine compound (**XIV**) may be BOC protected.
15   However, any suitable amine protecting group known in the art may
       be used.

       The attachment of a pre-formed PBD C-ring via peptide bonding and
       subsequent ring closure to form the PBD B-ring is known in the
20   art and is demonstrated in WO 00/12508. Briefly, the PBD C-ring

34

(as part of compound **XVI**) is attached to the compound **XV** via a peptide bond to give compound **XVII**. The NO₂ group in compound **XVII** is then reduced to the corresponding NH₂ group which is protected using any nitrogen protecting group known in the art.

5 Preferably this protecting group is a carbamate protecting group and more preferably this is an alloc protecting group. The PBD B-ring is then formed by ring closure of the compound **XVIII** to give compound **XIX**. The protecting group may then be removed from the chain at the C8 position to give the desired amine terminated

10 PBD capping group **XX**. An alternative method proceeding via an isocyanate intermediate is described in co-pending application GB 0321295.8.

The capping group **XX** may then be reacted with an acid terminated

15 linker chain through the amine group of the chain at the C8 position to attach the capping group to the linker chain.

An alternative method of synthesis comprises synthesising a N10/C11 protected PBD unit with an 8-OH substituent, and then

20 coupling this, under Mitsunobu conditions, to the protected amine of formula **XIV**.

Synthesis of carboxylic acid (or equivalent) terminated capping groups

25 The carboxylic acid terminated linker compound (**XXI**) shown below is made from the known carboxylic acid ester (Tercel *et al.*, *J. Med. Chem.*, 2003, 46, 2132-2151):

30

35

Methylation of the ester at the hydroxyl position on C11 followed by saponification of the methyl ester, preferably using NaOH, gives the corresponding acid terminated PDB capping group **XXI** which is protected at both the N10 and C11 positions.

5

It is envisaged that other acid terminated capping units could be formed by the same general synthesis strategy with different substituents at the C7 position and/or a different chain at the C8 position, although still terminating in the methyl ester group

10   and/or possible different N10 and C11 protecting groups and optionally substituents at the C2 and/or C3 positions of the PBD C-ring.

The acid terminated capping group **XXI** can then be linked to an

15   amine terminated linker group via a peptide bond. Where the substituents present on the acid terminated capping group are different from those shown in **XXI**, it is important that they are stable under the coupling conditions used to link the capping group to the linking group. It is possible that alternative

20   substituent groups may be altered by the coupling reaction however unwanted side reactions should be avoided. It is clear to a person skilled in the art that careful choice of substituent groups and protecting groups on the acid terminated capping group will ensure that unwanted side reactions are minimised.

25

Synthesis of carboxylic acid (or equivalent) terminated linker units
The simplest acid terminated linker units, which fall under the description of T above, are of the form HOOC-Q-COOH where Q is as

30   defined above. In this case the units may be used directly to link two amine terminated capping units through the general coupling reactions shown in scheme 1. However, more complex linker units are envisaged that may be synthesised as follows:

Scheme 4

5   The diacid linker unit **XXII** may be coupled by peptide bonds to
     two acid-protected amine groups **(XXIV)** to form an acid protected
     dipeptide linker unit **(XXV)** that may subsequently be deprotected
     to form the diacidic linking unit **XXVI**.

10   Initial activation of the diacid **XXII** to form the acid chloride
     XXIII is preferably performed using oxalyl chloride. In scheme
     4, activation of the diacid compound **XXII** is shown as proceeding
     via the acid chloride however any activation step known in the
     art may be used to form an active ester analogue of compound
15   **XXIII** for reaction with the amine group on compound **XXIV**.
     Alternatively, a coupling initiator, as described above, could be
     used to couple the diacid **XXII** and the protected amine **XXIV**.

     Importantly the acid group on compound **XXIV** is protected so that
20   the peptide bond formation occurs favourably between the
     activated compound **XXIII** and the amine group on compound **XXIV**.

     Following coupling, the dipeptide **XXV** may be deprotected to give
     the diacidic linker compound **XXVI**. Compound **XXVI** may then be
25   used either to react with an amine functional group on an amine
     terminated capping unit to form a dimer of formula **I**, or to react
     with an amine functional group on a separate molecule to further

lengthen the linker chain. For example reaction with a molecule
of the general formula H_2N-G'-COOBn, in an analogous manner to
the reaction shown in scheme 4, could be used to produce a linker
molecule of the general formula:

5   HOOC-G'-NH-C(=O)-G-NH-C(=O)-Q-C(=O)-NH-G-C(=O)-NH-G'-COOH
       (equivalent to:
       HOOC-G'-NH-Het-T-Het'-NH-G'-COOH)

       By repeated use of the general synthesis outlined in scheme 4,
10   the skilled person could build up linker chains with a range of
       different G groups by successive addition of H_2N-$G^{n\prime}$-COOBn
       molecules. These units could then be coupled in the same way as
       compounds of the formula **XXV** to acid terminated capping units
   **(VIII)** to form compounds of formula **I**.

15

       The $G^{n\prime}$ motif is used above to indicate that successive G groups
       in the linker unit need not necessarily be identical. It will be
       clear to the person skilled in the art that reaction with
       successive H_2N-$G^{n\prime}$-COOBn groups in which the $G^{n\prime}$ groups differ
20   would result in linker chains formed comprising different
       heteroarylene groups.

       Furthermore, orthogonal protection of both ends of the diacid
       compound **XXII** (or any diacid linker unit formed by addition of
25   one or more H_2N-$G^{n\prime}$-COOBn groups) followed by selective
       deprotection of one of the acid groups may allow linker units to
       be formed which do not have the same number of G units on each
       side of the T unit.

30   Preferably the number of $G^{n\prime}$ units on each side of the T unit is
       between 0 and 8, more preferably between 0 and 5, more preferably
       between 0 and 3.

       In the above discussion, the compound **XXIV** is shown with a Bn
35   acid-protecting group. It is envisaged that any other acid-
       protecting group known in the art may be used as an alternative
       to the Bn group shown.

It is also envisaged that the Het units in the general formula **I** may be interrupted by spacer units (L) which alter the spacing between one Het group and the next. The identity of the possible

5   L groups is as defined above i.e. β-alanine, glycine, 3-aminobutanoic acid (or a single bond, i.e. no L unit). Where L is an amino acid the addition of an L spacer group to the linker chain may be achieved as shown below:

q = 1 to 3

10

Scheme 5

At any stage in the synthesis of the linker group wherein a compound is deprotected to give an acid, a spacer (L) group may be coupled to this acid by formation of a peptide bond. In

15   scheme 5 above, two routes are shown to achieve this coupling, either via activation of the acid, to the acid chloride, followed by addition of the hydroxyl-protected spacer group or by direct peptide bond formation between the acid compound and the hydroxyl-protected spacer group. In both cases subsequent

20   deprotection of the hydroxyl group results in the corresponding acid product.

As mentioned above, any activation step known in the art may be used to form an active ester analogue of the acid chloride

25   compound. Also, any peptide bonding initiator known in the art may be used as an alternative to the HOBt/EDCI shown in scheme 5. Suitable peptide bonding initiator groups are as mentioned above.

This acid product may then be further coupled to a G group via a

30   peptide bond in a similar manner to that shown in scheme 4. By

39

using this general method of reacting an acid compound with an
hydroxyl-protected amino acid followed by deprotection of the
hydroxyl group, linker chains can be built up comprising Het
groups and L spacer groups in various arrangements.

5

An example of a suitable hydroxyl protecting group is a Bn group.
Preferably a spacer unit (L) is inserted into the linker chain
after between 3 and 5 consecutive Het units. It is preferred
that no more than 5 Het units occur consecutively in the linker

10   chain without being interrupted by a spacer unit (L). More
      preferably no more than 3 Het units occur consecutively in the
      linker chain without being interrupted by a spacer unit (L).

The final deprotected acidic compound may then be coupled to an

15   amine terminated capping unit (V) in a manner described in scheme
      1 to give a product of formula I.

Synthesis of amine terminated linker units
The simplest amine terminated linker units, which fall under the

20   description of T above, are of the form $H_2N-Q-NH_2$ where Q is as
      defined above. In this case the units may be used directly to
      link two carboxylic acid (or equivalent) terminated capping
      units. However, more complex linker units are envisaged that may
      be synthesised as follows:

25

Scheme 6
In scheme 6, the dipeptide compound **XXIX** is formed via an

30   elimination reaction between compounds of the general formula

40

XXVII and **XXVIII**. The two nitro groups on the dipeptide may then be reduced to form the diamine compound **XXX**. The reduction reaction is preferably a hydrogenation reaction performed with Pd/C and H_2 under pressure in a Parr apparatus.

5

The diamine **XXX** may then be used to react directly, under peptide coupling conditions, with carboxylic acid terminated capping units (**VIII**) to form compounds of formula **I**.

10   Alternatively, it is also envisaged that the compounds of formula **XXX** may be further reacted with other compounds to lengthen the linker chain. For example, reaction of compound **XXX** with a compound of the general formula $O_2N-G'-C(=O)-CCl_3$ could be used to give compounds of the general formula:

15   $O_2N-G'-C(=O)-NH-G-C(=O)-NH-Q-NH-C(=O)-G-NH-C(=O)-G'-NO_2$
(equivalent to:
$O_2N-G'-C(=O)-Het-T-Het'-C(=O)-G'-NO_2$)
Reduction of these molecules under conditions as described above may then give the corresponding diamine linker unit. These could

20   then be coupled under peptide coupling conditions to carboxylic acid terminated capping units (**VIII**) to form a compound of formula **I**.

By repeated use of the general synthesis outlined in scheme 6,

25   the skilled person could build up linker chains with a range of different G groups by successive addition of $O_2N-G^{n'}-C(=O)-CCl_3$ molecules.

The $G^{n'}$ motif is used above to indicate that successive G groups

30   in the linker unit need not necessarily be identical. It will be clear to the person skilled in the art that reaction with successive $O_2N-G^{n'}-C(=O)-CCl_3$ groups in which the $G^{n'}$ groups differ would result in linker chains formed comprising different heteroarylene groups.

35

41

Furthermore, orthogonal protection of both ends of the diamine compound **XXVIII** (or any diamine linker unit formed by addition of one or more $O_2N-G^{n\prime}-C(=O)-CCl_3$ groups) followed by selective deprotection of one of the amine groups may
5   allow linker units to be formed which do not have the same number of G units on each side of the T unit.

Preferably the number of $G^{n\prime}$ units on each side of the central T unit is between 0 and 5, more preferably 0 and 3.
10

In scheme 6 above, compound **XXVII** may be derived from a corresponding carboxylic acid by activation to substitute the activating CCl_3 group onto the acid. It is also envisaged that compound **XXVII** may be any other activated compound derived from a
15   corresponding carboxylic acid, for example the acid chloride or acid bromide analogues. Also, the coupling reaction may be performed directly from the carboxylic acid from which **XXVII** is derived on reaction with compound **XXVIII** in the presence of a peptide coupling initiator as described above.
20

Furthermore, reaction of the compounds of formula **XXX** with a compound of the general formula $ZO-C(=O)-G\prime-NHZ\prime$ where Z and Z' are oxygen and nitrogen protecting groups respectively could be used to give linker units as shown below:
25

42

Scheme 7

5   In scheme 7, Z is any oxygen protecting group known in the art
    although it is preferable that Z is removed under the peptide
    coupling conditions. Z may alternatively be an activating group
    derived from any peptide coupling reagent known in the art, for
    example BOP, BOP-Cl, DCC, DIC, EDPP, HATU, HOBt, PyBroP or
10 TBTU, that activates compound **XXXI** to peptide coupling reactions.
    Preferably OZ is OBt, Cl or Br. Also Z′ is any nitrogen
    protecting group known in the art although it is preferable that
    Z′ is not removed under the peptide coupling conditions, more
    preferably Z′ is BOC, Fmoc, CBz, Alloc, Teoc, Adoc, Troc, Doc,
15 Hoc or TcBOC. Removal of Z′ from compound **XXXII** to deprotect the
    diamine gives compound **XXXIII**. This may then be used as a linker
    unit to couple two acid terminated capping units (**VIII**) via
    peptide bond formation resulting in a compound of formula **I**.

20 It is also envisaged that the Het units in the general formula **I**
    may be interrupted by spacer units (L) which alter the spacing
    between one Het group and the next. The identity of the possible
    L groups is as defined above i.e. β-alanine, glycine, 3-
    aminobutanoic acid (or a single bond, i.e. no L group). Where L

43

is an amino acid, the addition of an L spacer group to the linker
chain may be achieved as shown below:

q = 1 to 3

Scheme 8

At any stage in the synthesis of the linker group wherein a
compound is deprotected to give an amine, a spacer (L) group may
be coupled to this amine by formation of a peptide bond. In
scheme 8 above, this coupling is achieved by peptide bond
formation between the amine compound and the nitrogen-protected
spacer group. Subsequent deprotection of the nitrogen group
results in the corresponding amine product. The hydroxyl group
of the acid moiety on the spacer group may also be protected with
a hydroxyl-protecting group which is removed under the peptide
bond formation conditions.

Following coupling of the spacer unit to the amine compound and
subsequent deprotection, the amine product may then be further
coupled to a G group via a peptide bond in a similar manner to
that shown in either scheme 6 or 7. By using this general method
of reacting an amine compound with a amine-protected amino acid
followed by deprotection of the amine group, linker chains can be
built up comprising Het groups and L spacer groups in various
arrangements.

The spacer unit (L) may be a β-alanine unit, a glycine unit or a
4-aminobutanoic acid unit.

The hydroxyl-protecting group in scheme 8 is shown as Bt.
However any other hydroxyl-protecting group known in the art is
also envisaged.

44

Preferably a spacer unit (L) is inserted into the linker chain after between 3 and 5 consecutive Het units. It is preferred that no more than 5 Het units occur consecutively in the linker chain without being interrupted by a spacer unit (L). More preferably no more than 3 Het units occur consecutively in the linker chain without being interrupted by a spacer unit (L).

The final unprotected amine compound may then be coupled to a carboxylic acid (or equivalent) terminated capping unit (**VIII**) in a manner described in scheme 2 to give a product of formula **I**.

Synthesis of compounds of general formula II

Compounds of the general formula **II** may be synthesised by the general synthetic route described below:

Scheme 9

In this general scheme, compound **XXXIV** comprises at least one G unit, and may optionally comprise further G and/or spacer (L) units coupled together as shown above. In this scheme, t = 0 to 12. Importantly, compound **XXXIV** has a nitrogen protected moiety and a hydroxyl protected moiety (Z' and Z respectively).

Removal of the Z hydroxyl protecting moiety gives the unprotected acid compound **XXXV**. Preferably Z forms an ester functional group on compound **XXXIV** and more preferably Z is C_{1-7} alkyl, even more preferably Z is methyl. In the preferred form where Z forms an

45

ester functional group, hydrolysis of the ester under standard conditions yields the free acid compound **XXXV**.

5   Compound **XXXV** is then coupled with an amine terminated capping unit (**V**), *via* an elimination reaction forming a peptide bond, to give compound **XXXVI**.

Subsequently, the nitrogen protecting group (Z′) on compound **XXXVI** is removed to give the free amine compound **XXXVII**.

10   Preferably the Z′ group is a carbamate nitrogen protecting group, more preferably Z′ is BOC. Where Z′ is BOC, HCl in dioxane is preferably used to cleave the BOC group to give the free amine.

The compound **XXXVII** is the coupled with an acid terminated

15   capping unit (**VIII**), again *via* an elimination reaction forming a peptide bond, to give the compound **XXXVIII**.

The joining of the linker chain to the amine and carboxylic acid terminated end cap units could be carried out in the reverse

20   order, with appropriate protection of the functional groups.

An alternative synthesis of compounds of formula **II** follows the method of WO 00/12509, where a PBD moiety is immobilised at the N10 position onto a solid support, and the linker chain is grown

25   from the C8 position, using amino-heteroarylene-carbonyl groups as the combinatorial units. The chain grown at the C8 position can then be capped with the appropriate terminated capping unit.

In the above mentioned embodiments, the optionally substituted

30   heteroarylene group (G) may alternatively be replaced with a C_{5-6} arylene-C_{5-6} arylene group or a C_{8-10} heteroarylene-C_{5-20} arylene group. C_{5-6} arylene-C_{5-6} arylene groups are as defined in copending application entitled "amino acids" filed on 1 March 2004.

35

In the C_{8-10} heteroarylene-C_{5-20} arylene moiety described above, the C_{8-10} heteroarylene group comprises two fused rings.

46

The term arylene, as used herein, pertains to a divalent moiety obtained by removing two hydrogen atoms from aromatic ring atoms of an aromatic compound having from 5 to 20 ring atoms. Arylene
5   compounds as described herein correspond to aryl groups as defined above with one fewer hydrogen atoms on the ring atoms. Preferably, the C_{5-20} arylene group is a C_{5-7} arylene group and more preferably a C_{5-6} heteroarylene group.

10   Het units comprising a carbonyl-C_{8-10} heteroarylene-C_{5-6} heteroarylene-amino unit have been described in Briehen, C.A., *et al.*, *Chem. Eur. J.*, **9**, 2110-2122 (2003) and Renneberg, D., *et al.*, *J. Am. Chem. Soc.*, **125**, 5707-5716 (2003) and include:

Further preferences

20   The following preferences may apply to all aspects of the invention as described above, or may relate to a single aspect. The preferences may be combined together in any combination.

It is preferred that PBD and PBD' are the same.

25

R^9 is preferably H.

R^2 is preferably R, and is more preferably an optionally substituted C_{5-20} aryl group. Most preferred is an optionally
30   substituted phenyl group.

R^6 is preferably selected from H, OH, OR, SH, NH_2, nitro and halo, and is more preferably H or halo, and most preferably is H.

47

R^7 is preferably independently selected from H, OR, SH, SR, NH_2, NHR, NRR', and halo, and more preferably independently selected from H and OR, where R is preferably selected from optionally substituted C_{1-7} alkyl, C_{3-10} heterocyclyl and C_{5-10} aryl groups.

5 Preferably R^7 is OMe or H and most preferably OMe.

R^{10} is preferably H, BOC, Troc or alloc and is most preferably H or alloc.

10 R^{11} is preferably THP or a silyl oxygen protecting group (for example TBS) and is most preferably THP.

In other embodiments of the invention, R^{10} and R^{15} together form a double bond between N10 and C11.

15

A is preferably NH, O or a single bond and most preferably NH or O.

Y is preferably a single bond or C_{1-7} alkyl, more preferably a

20 single bond or C_3 alkyl.

In the first aspect of the invention, Het and Het' are preferably selected from the same class of amino-heteroarylene-carbonyl units.

25

A preferred class of amino-heteroarylene-carbonyl units are those based on nitrogen containing heteroarylene units, and in particular N-containing C5 heteroarylene units. These N-containing heteroarylene units are preferably substituted on one

30 N atom with a C_{1-4} alkyl group, which is more preferably methyl. A particularly preferred sub-class comprises the following three units:

48

N-methyl-pyrrole

Hydroxy-N-methyl-pyrrole

1-N-methyl-imidazole

Other preferred units have heteroarylene groups based on 2-(pyrrol-2-yl)benzimidazoles, 2(pyrrol-2-yl)imiazopyridines and 5-hydroxy(pyrrol-2-yl)benzimadozles.

In the first aspect of the invention, the sums na + nb + nc and nd + ne + nf are preferably equal and are both more preferably between 1 and 3.

In the second aspect of the invention, the total number of Het groups in the compound (i.e. the sum ng + (nj x nh)) is preferably 1 to 3 and is more preferably 1 or 3.

Examples

Example 1: Synthesis of dimer 1 (SJG-605)

a) 1-Methyl-1H-pyrrole-2,5-dicarboxylic acid bis-[(11S, 11aS)(11-hydroxy-7-methoxy-10-(carboxylic acid allyl ester)-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)-amide] (6).

49

(3)   (4)   (5)

(6)

A catalytic amount of DMF (1 drop) was added to a stirred
solution of the bis-acid **3** (49 mg, 0.29 mmol, *J. Org. Chem.*, 43,
5   1978, 4849-53) and oxalyl chloride (81 mg, 55 µL, 0.63 mmol) in
anhydrous THF (5 mL) at room temperature. Initial effervescence
was observed and the mixture was allowed to stir for a further 4
h. The acid chloride solution was added dropwise to a solution
of the aniline **5** (200 mg, 0.58 mmol, *Bioorg. & Med. Chem. Lett.*,
10   *13, 2003, 2277-80*) and Et_3N (129 mg, 177 µL, 1.27 mmol) at 0 °C
(ice/acetone) under a N_2 atmosphere. The reaction mixture was
allowed to warm to room temperature and stirring was continued
for 16 h. Analysis of the reaction mixture by TLC (90:10 v/v
$CHCl_3$/MeOH) revealed amide formation. Excess THF was removed by
15   rotary evaporation under reduced pressure and the resulting
residue was dissolved in CH_2Cl_2 (30 mL). The organic phase was
washed with saturated aqueous 1N HCl (3 x 10 mL), sat[d] aqueous
$NaHCO_3$ (10 mL), H_2O (10 mL), brine (10 mL) and dried ($MgSO_4$). The
mixture was filtered and excess solvent removed by rotary
20   evaporation under reduced pressure to afford the crude product as
a thin film. The crude material was subjected to flash column
chromatography (Neat $CHCl_3$ then 99:1 v/v $CHCl_3$/MeOH) and removal
of excess eluent isolated the pure amide **6** as a white foam (161
mg, 68%): $[\alpha]^{20}_D$ = +38° (*c* = 0.17, $CHCl_3$); ^{1}H NMR (400 MHz, $CDCl_3$)
25   δ 8.46 (s, 2H), 8.44 (s, 2H), 7.30 (s, 2H), 6.71 (s, 2H), 5.92-
5.75 (m, 2H), 5.74-5.60 (m, 2H), 5.24-5.08 (m, 4H), 4.67 (dd, 2H,

50

J = 13.1, 5.0 Hz), 4.59-4.46 (m, 2H), 4.26 (s, 3H), 4.00 (s, 6H),
3.77-3.69 (m, 2H), 3.61-3.47 (m, 4H), 2.22-1.96 (m, 8H); ^{13}C NMR
(100 MHz, CDCl$_3$) δ 166.8, 158.9, 156.2, 146.8, 132.0, 131.3,
129.9, 128.7, 128.5, 120.4, 117.9, 111.4, 109.5, 86.0, 66.9,
60.1, 56.4, 46.5, 34.8, 28.8, 23.1; IR (CHCl$_3$) 3417, 2976, 2954,
2879, 1707, 1689, 1628, 1609, 1589, 1519, 1480, 1460, 1430, 1411,
1380, 1340, 1313, 1275, 1249, 1200, 1039 cm^{-1}; MS (FAB) m/z
(relative intensity) 850 ($[M + Na]^{+\cdot}$, 21), 810 (15), 766 (23), 419
(33), 379 (100), 326 (67), 272 (41), 232 (79); HRMS $[M + Na]^{+\cdot}$
calcd for C$_{41}$H$_{45}$N$_7$O$_{12}$Na m/z 850.3024, found (FAB) m/z 850.2991.

*b) 1-Methyl-1H-pyrrole-2,5-dicarboxylic acid bis-[(11aS)(7-
methoxy-5-oxo-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-
c][1,4]benzodiazepin-8-yl)-amide] (1).*

(6)

(1) SJG-605

A catalytic amount of tetrakis(triphenylphosphine)palladium (9.9
mg, 8.5 µmol) was added to a stirred solution of the protected
PBD (**6**) (141 mg, 0.17 mmol), Ph$_3$P (4.5 mg, 17.0 µmol) and
pyrrolidine (25 mg, 30 µL, 0.36 mmol) in CH$_2$Cl$_2$ (10 mL) under a N$_2$
atmosphere. The reaction mixture was allowed to stir at room
temperature and the progress of reaction monitored by TLC (90:10
v/v CHCl$_3$/MeOH), after 2.5 h the reaction was complete. The
solvent was evaporated under reduced pressure and the resulting
residue subjected to flash chromatography (98:2 v/v CHCl$_3$/MeOH)

51

to give **1** (SJG-605) as a pale orange glass which was repeatedly evaporated *in vacuo* with $CHCl_3$ to provide the imine form (90 mg, 85%): $[\alpha]^{20}_D = +550°$ (c = 0.45, $CHCl_3$); ^1H NMR (400 MHz, $CDCl_3$) δ 8.47 (s, 2H), 8.43 (s, 2H), 7.70 (d, 2H, J = 4.4 Hz), 7.56 (s, 2H), 6.74 (s, 2H), 4.27 (s, 3H), 4.00 (s, 6H), 3.86-3.79 (m, 2H), 3.77-3.69 (m, 2H), 3.63-3.52 (m, 2H), 2.38-2.28 (m, 4H), 2.19-1.95 (m, 4H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 164.5, 162.6, 159.0, 146.2, 140.7, 131.2, 130.3, 122.6, 117.7, 111.5, 110.2, 56.3, 53.6, 46.7, 34.7, 29.6, 24.1; IR ($CHCl_3$) 3417, 2976, 2878, 1683, 1605, 1574, 1477, 1456, 1429, 1381, 1340, 1257, 1201, 1178, 1082, 1018 cm^{-1}; MS (FAB) m/z (relative intensity) 624 ($[M + H]^{+\cdot}$, 100), 571 (10), 395 (15), 379 (63), 326 (23), 307 (54), 289 (29); HRMS $[M + H]^{+\cdot}$ calcd for $C_{33}H_{34}N_7O_6$ m/z 624.2571, found (FAB) m/z 624.2544.

**Example 2: Synthesis of dimer 2 (SJG-604)**

a) 1-Methyl-1H-pyrrole-2,4-dicarboxylic acid bis-[(11S, 11aS)(11-hydroxy-7-methoxy-10-(carboxylic acid allyl ester)-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)-amide] (9).

52

A catalytic amount of DMF (1 drop) was added to a stirred solution of the di-acid (7) (49 mg, 0.29 mmol) and oxalyl chloride (81 mg, 55 µL, 0.63 mmol) in anhydrous THF (5 mL) at room temperature. Initial effervescence was observed and the
5   mixture was allowed to stir for a further 15 min. The acid chloride solution was added dropwise to a solution of the aniline capping unit **5** (200 mg, 0.58 mmol, *Bioorg. & Med. Chem. Lett.,* *13, 2003, 2277-80*) and Et$_3$N (129 mg, 177 µL, 1.27 mmol) at 0 °C (ice/acetone) under a N$_2$ atmosphere. The reaction mixture was
10   allowed to warm to room temperature and stirring was continued for 16 h. Analysis of the reaction mixture by TLC (90:10 v/v CHCl$_3$/MeOH) revealed amide formation. Excess THF was removed by rotary evaporation under reduced pressure and the resulting residue was dissolved in CH$_2$Cl$_2$ (30 mL). The organic phase was
15   washed with saturated aqueous 1N HCl (3 x 15 mL), sat^d aqueous NaHCO$_3$ (15 mL), H$_2$O (15 mL), brine (15 mL) and dried (MgSO$_4$). The mixture was filtered and excess solvent removed by rotary evaporation under reduced pressure to afford the crude product as a thin film. The crude material was subjected to flash column
20   chromatography (Neat CHCl$_3$ then 99:1 v/v CHCl$_3$/MeOH) and removal of excess eluent isolated the pure amide **9** as a white solid (168 mg, 71%): $[\alpha]^{21}_D$ = +40° (*c* = 0.15, CHCl$_3$); ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.48-8.34 (m, 3H), 8.24-8.17 (m, 1H), 7.36 (s, 1H), 7.30 (s, 2H), 7.12 (s, 1H), 5.89-5.74 (m, 2H), 5.72-5.62 (m, 2H), 5.22-
25   5.08 (m, 4H), 4.72-4.59 (m, 2H), 4.58-4.47 (m, 2H), 4.11-3.95 (m, 9H), 3.77-3.68 (m, 2H), 3.61-3.45 (m, 4H), 2.22-1.91 (m, 8H); ^{13}C NMR (100 MHz, CDCl$_3$) δ 166.9, 166.8, 161.3, 158.7, 156.1, 146.9, 146.8, 132.0, 130.0, 129.8, 128.8, 128.6, 128.4, 128.2, 127.1, 120.8, 120.5, 119.0, 117.8, 111.5, 109.5, 86.0, 66.8, 60.1, 56.4,
30   46.5, 37.5, 28.8, 23.1; IR (CHCl$_3$) 3418, 2978, 2880, 1704, 1682, 1633, 1609, 1589, 1552, 1520, 1463, 1433, 1411, 1313, 1261, 1218, 1134, 1040 cm^{-1}; MS (FAB) *m/z* (relative intensity) 960 ([*M* + Cs]$^{+\cdot}$, 100), 850 ([*M* + Na]$^{+\cdot}$, 8), 464 (10), 419 (28); HRMS [*M* + Na]$^{+\cdot}$ calcd for C$_{41}$H$_{45}$N$_7$O$_{12}$Na *m/z* 850.3024, found (FAB) *m/z*
35   850.2991.

53

b) 1-Methyl-1H-pyrrole-2,4-dicarboxylic acid bis-[(11aS)(7-methoxy-5-oxo-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)-amide] (2).

(9)

(2) SJG-604

5   A catalytic amount of tetrakis(triphenylphosphine)palladium (10.9 mg, 9.4 µmol) was added to a stirred solution of the protected PBD (**9**) (156 mg, 0.19 mmol), Ph$_3$P (5.0 mg, 19.0 µmol) and pyrrolidine (28 mg, 33 µL, 0.40 mmol) in CH$_2$Cl$_2$ (10 mL) under a N$_2$ atmosphere. The reaction mixture was allowed to stir at room

10   temperature and the progress of reaction monitored by TLC (90:10 v/v CHCl$_3$/MeOH), after 2 h the reaction was complete. The solvent was evaporated under reduced pressure and the resulting residue subjected to flash chromatography (98:2 v/v CHCl$_3$/MeOH) to give **2** (SJG-604) as a pale orange glass which was repeatedly

15   evaporated *in vacuo* with CHCl$_3$ to provide the imine form (99 mg, 84%): $[\alpha]^{19}_D$ = +433° (*c* = 0.49, CHCl$_3$); ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.38 (s, 2H), 8.30 (s, 1H), 8.21 (s, 1H), 7.61 (d, 2H, *J* = 4.3 Hz), 7.47 (s, 1H), 7.46 (s, 1H), 7.33 (d, 1H, *J* = 1.65 Hz), 7.11 (d, 1H, *J* = 1.75 Hz), 3.94-3.92 (m, 9H), 3.80-3.70 (m, 2H), 3.69-

20   3.59 (m, 2H), 3.55-3.43 (m, 2H), 2.30-2.11 (m, 4H), 2.09-1.85 (m, 4H); ^{13}C NMR (100 MHz, CDCl$_3$) δ 163.5 (2 signals), 161.6, 161.5, 160.4, 157.9, 145.3, 145.1, 139.7, 139.6, 129.6, 129.3, 129.1, 128.9, 126.0, 121.6, 121.3, 117.9, 116.9, 116.8, 110.6, 109.3,

54

109.1, 55.3, 52.7, 45.7, 36.5, 28.6, 23.2; IR (CHCl$_3$) 3417, 2975, 2877, 1667, 1605, 1575, 1552, 1510, 1480, 1463, 1340, 1260, 1214, 1179, 1020 cm^{-1}; MS (FAB) m/z (relative intensity) 640 ([M + Na]$^{+\cdot}$, 9), 624 ([M + H]$^{+\cdot}$, 63), 592 (11), 395 (20), 379 (100), 365 (9), 326 (15), 307 (23); HRMS [M + H]$^{+\cdot}$ calcd for C$_{33}$H$_{34}$N$_7$O$_6$ m/z 624.2571, found (FAB) m/z 624.2544.

Example 3: Synthesis of an amino capping unit 10

a) *4-(3-tert-Butoxycarbonylamino-propoxy)-5-methoxy-2-nitro-benzoic acid (35).*

A solution of diethylazodicarboxylate (16 mL, 0.10 mol) in anhydrous THF (200 mL) was added dropwise to a stirred solution of 4-Hydroxy-5-methoxy-2-nitro-benzaldehyde (20g, 0.10 mol *J. Am. Chem. Soc., 112, 1990, 7050-51*), (3-Hydroxy-propyl)-carbamic acid *tert*-butyl ester (17.35 mL, 0.10 mol), and triphenylphospine (26.63 g, 0.10 mol) in anhydrous THF (800 mL). The reaction mixture was allowed to stir overnight after which time the solvent was removed *in vacuo*. The residue was triturated with toluene (500 mL) and filtered. The resulting filtrate was washed with 1N aqueous NaOH (300 mL), brine (300 mL), dried (MgSO$_4$), filtered and evaporated *in vacuo*. The residue was triturated with diethyl ether (400 mL) and the precipitate was collected by filtration and then air dried to yield a pale yellow solid (20 g), which contained the desired product contaminated by some side-reaction products. This batch was used directly in the next step without any further purification. The solid was dissolved in acetone (200 mL) and vigorously stirred. A hot solution (85°C) of KMnO$_4$ (20g) in water (200 mL) was added dropwise to the mixture where vigorous reflux occurred. The reaction mixture was stirred for 1 h after which time it was filtered through celite. The acetone was removed *in vacuo* and the remaining aqueous phase

55

was basified to pH 10 with 1N aqueous sodium hydroxide. The
solids were removed by filtration and the filtrate was washed
with EtOAc (400 mL). The aqueous phase was acidified to pH 2-3
with concentrated aqueous citric acid and the resulting

5   suspension was extracted with EtOAc (400 mL), washed with brine
(100 mL), dried (MgSO$_4$), filtered and the solvent was removed *in
vacuo* to yield **35** (12g, 32% over two steps) as a dark oil that
solidifies in the freezer. A sample was recrystallised from
EtOAc to yield a white solid, which provided analytical data: [1]H

10   NMR (400 MHz, DMSO-*d$_6$*) δ 7.56 (s, 1H), 7.30 (s, 1H), 6.91 (t, *J* =
5 Hz, 1H), 4.11 (t, *J* = 6.0 Hz, 2H), 3.92 (s, 3H), 3.10 (q, *J* =
6.0 Hz, 2H), 1.86 (p, *J* = 6.3 Hz, 2H), 1.38 (s, 9H); ^{13}C NMR (100
MHz, DMSO-*d$_6$*) δ 166.0, 155.6, 151.7, 149.4, 141.3, 121.0, 111.2,
107.8, 77.5, 66.9, 56.4, 36.8, 28.8, 28.2.

15

*b) {3-[4-(2S-Hydroxymethyl-pyrrolidine-1-carbonyl)-2-methoxy-5-
nitro-phenoxy]-propyl}-carbamic acid tert-butyl ester (36).*

(35)   (36)

20   A solution of **35** (5.36 g, 14.4 mmol), EDCI (4.16 g, 21.7 mmol),
and HOBt (3.32 g, 21.7 mmol) in anhydrous DMF (80 mL) were
stirred at 30°C for 3 h. Pyrrolidine-methanol (1.57 mL, 15.9
mmol) was added slowly at room temperature and the reaction was
allowed to stir overnight. The following day the reaction

25   mixture was diluted with EtOAc (250 mL) and washed with 10%
aqueous citric acid (100 mL), water (2 x 200 mL), sat[d] aqueous
NaHCO$_3$ (200 mL), brine (200 mL), dried (MgSO$_4$), filtered and the
solvent was removed *in vacuo* to yield **36** (6.1 g, 93%) which was
pure as observed by TLC (EtOAc): ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.68

30   (s, 1H), 6.81 (s, 1H), 5.24 (m, 1H), 4.38 (m, 2H), 4.18 (t, *J* =
5.7 Hz), 3.99 (s, 3H), 3.95-3.80 (m, 2H), 3.38 (m, 2H), 3.18 (t,
J = 6.6 Hz, 2H), 2.19-1.74 (m, 6H), 1.45 (s, 9H); ^{13}C NMR (100
MHz, CDCl$_3$) δ 156.0, 154.7, 148.4, 137.1, 128.0, 109.0, 108.1,

79.2, 68.4, 66.1, 61.5, 56.7, 49.5, 38.4, 29.1, 28.4, 24.4;
Calculated for $C_{21}H_{31}N_3O_8$: C 55.62, H 6.89, N 9.27. Found : C
55.45, H 7.03, N 9.05.

c) *[5-(3-tert-Butoxycarbonylamino-propoxy)-2-(2S-hydroxymethyl-*
pyrrolidine-1-carbonyl)-4-methoxy-phenyl]-carbamic acid allyl
ester (37).

(36)   1) Hydrogenation   (37)
              2) Alloc protection

A slurry of **36** (6.1 g, 13.4 mmol) and 10% Pd/C (600 mg) in EtOAc
(100 mL) was hydrogenated at 45 PSI using Parr apparatus. When
hydrogen uptake ceased, the reaction was stopped and TLC analysis
revealed completion of the reaction. The suspension was filtered
through celite, the filtrate was dried ($MgSO_4$), filtered and the
solvent removed *in vacuo*. The crude aniline was dissolved in
anhydrous DCM (200 mL) in the presence of anhydrous pyridine
(2.34 mL, 28.9 mmol) and stirred at 0°C (acetone/ ice bath). A
solution of allyl chloroformate (1.28 mL, 12.1 mmol) in anhydrous
DCM (60 mL) was added dropwise and the mixture was allowed to
stir at room temperature overnight. The following day, the
reaction mixture was washed with 10% aqueous citric acid (100
mL), water (200 mL), sat^d aqueous $NaHCO_3$ (200 mL), brine (200 mL),
dried ($MgSO_4$), filtered and the solvent removed *in vacuo* to yield
37 (5.85 g, 86%): ^1H NMR (400 MHz, $CDCl_3$) δ 8.76 (br s, 1H), 7.77
(s, 1H), 7.26 (s, 1H), 5.98 (m, 1H), 5.47 (m, 1H), 5.38-5.24 (dd,
2H), 4.63 (d, 2H), 4.45-4.20 (m, 2H), 4.15 (m, 2H), 3.85 (m, 4H),
3.80-3.45 (m, 3H), 3.35 (m, 2H), 2.18-1.60 (m, 6H), 1.46 (s, 9H);
^{13}C NMR (100 MHz, $CDCl_3$) δ 170.8, 156.0, 153.6, 150.3, 144.0,
132.5, 131.8, 118.1, 111.0, 105.5, 78.9, 68.6, 68.0, 65.8, 61.0,
56.3, 38.8, 31.5, 29.1, 28.5, 28.3, 22.6; IR ($CHCl_3$) 3398, 2973,
1711, 1597, 1523, 1457, 1407, 1328, 1228, 1204, 1172, 1117, 1052,
917, 730 cm^{-1}; $[\alpha]^{25}_D$ = -80° (*c* = 0.3, $CHCl_3$).

57

d) (11S, 11aS)-8-(3-tert-Butoxycarbonylamino-propoxy)-11-hydroxy-7-methoxy-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-10 carboxylic acid allyl ester (38).

A solution of **37** (5.85 g, 11.5 mmol), diacetoxy-iodobenzene (4.1 g, 12.7 mmol) and TEMPO (182 mg, 1.15 mmol) in DCM (100 mL) was allowed to stir overnight. The following day, TLC (EtOAc) revealed completion of the reaction and the organic phase was washed with sat^d sodium metabisulphite, sat^d aqueous NaHCO$_3$, brine, dried (MgSO$_4$), filtered and the solvent was removed *in vacuo*. The residue was purified by column chromatography (gradient elution from 60:40 EtOAc/Hexane to 100% EtOAc). The pure fractions were evaporated *in vacuo* to yield the ring-closed product **38** as a white foam (4.19 g, 72%): ^{1}H NMR (400 MHz, CDCl$_3$) δ 7.24 (s, 1H), 6.67 (s, 1H), 5.80 (m, 1H), 5.64 (m, 1H), 5.47 (m, 1H), 5.13 (m, 2H), 4.68 (m, 1H), 4.45 (m, 1H), 4.15-3.98 (m, 2H), 3.92 (s, 3H), 3.78-3.67 (m, 1H), 3.60-3.42 (m, 2H), 3.34 (m, 2H), 2.18-1.95 (m, 6H); ^{13}C NMR (100 MHz, CDCl$_3$) δ 167.0, 156.1, 156.0, 149.8, 148.5, 131.8, 128.3, 126.1, 118.0, 113.7, 110.5, 86.0, 79.0, 68.2, 66.7, 60.4, 60.0, 56.0, 46.4, 38.8, 29.1, 28.7, 28.5, 23.0; MS (ES$^+$) m/z (relative intensity), 506 ([M + H]$^{+\cdot}$, 100). **38** was optically pure as observed by chiral HPLC and is optically stable to treatment with TFA and extraction with conc^d NH$_4$OH.

*e) (11S, 11aS)-8-(3-Amino-propoxy)-11-hydroxy-7-methoxy-1,2,3,10,11,11aS-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carboxylic acid allyl ester (10).*

(38) → BOC removal → (10)

A mixture of **38** (1.1 g, 2.17 mmol), TFA (4 mL), DCM (6 mL) and
water (0.5 mL) was stirred for 20 min at room temperature. After
which time, TLC (CHCl₃) analysis revealed completion of the

5   reaction. The mixture was diluted with ice and basified to pH 10
or greater with aqueous NH₄OH. The aqueous solution was then
extracted with CHCl₃ (2 x 100 mL) and the combined organic layers
washed with brine, dried (MgSO₄), filtered and the solvent was
removed *in vacuo* to yield a white powder, which was pure as

10 observed by TLC (90:10:1 v/v/v CHCl₃/MeOH/NH₄OH) (880 mg, 100%).
This unstable amino capping unit **10** was used directly in the next
coupling step without further purification.

**Example 4 Synthesis of the dimer (13) AT217**

15

a) Preparation of 18.

(4) + (10) → coupling → (18)

Oxalyl chloride (47 µL, 0.55 mmol) was added to a stirred
solution of the diacid **3** (42 mg, 0.25 mmol) in anhydrous THF (5

20 mL) at room temperature. The mixture was then treated with a
drop of DMF at which point vigorous effervescence occurred. The
mixture was allowed to stir for 20 min at which point all
effervescence had stopped. This acid chloride solution was then

59

added dropwise to a stirred solution of the amide capping unit **10** (200 mg, 0.49 mmol) and TEA (151 µL, 1.08 mmol) in anhydrous THF (5 mL) at 0 °C under a nitrogen atmosphere. A white precipitate formed during the addition and the reaction mixture was allowed

5   to warm to room temperature. After 4 h, the solvent was removed *in vacuo* and the residue was partitioned between $CHCl_3$ (30 mL) and aqueous 1N HCl (20 mL). The organic phase was washed with sat^d aqueous $NaHCO_3$, brine, dried ($MgSO_4$), filtered and evaporated *in vacuo* to yield **18** (230 mg, quantitative yield) as a white

10 powder which was used in the next step without further purification: ^1H NMR (400 MHz, DMSO-d_6) δ 8.26 (triplet, J = 5.27 Hz, 2H), 7.10 (s, 2H), 6.79 (s, 2H), 6.68 (s, 2H), 6.51 (broad s, 2H), 5.92-5-68 (m, 2H), 5.58-5.39 (m, 2H), 5.17-4.93 (m, 4H), 4.74-4.32 (m, 4H), 4.14-3.93 (m, 7H), 3.83 (s, 6H), 3.50 (m, 2H),

15 3.44-3.23 (m, 8H), 2.14-1.81 (m, 12H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 165.0, 161.2, 154.4, 149.4, 147.0, 132.8, 129.0, 128.6, 116.9, 114.3, 110.7, 110.3, 85.4, 79.1, 66.6, 65.5, 64.9, 55.6, 45.0, 35.8, 33.9, 30.4, 28.8, 28.2, 25.1, 22.7, 15.1; MS (ES+) m/z (relative intensity) 944.5 ($[M + H]^{+\cdot}$, 35), 926.5 (40), 908.6

20 (100); IR ($CHCl_3$) 3320, 2928, 2246, 1709, 1627, 1535, 1513, 1464, 1435, 1409, 1312, 1277, 1218, 1134, 1104, 1054, 1014, 913, 871, 770, 731, 646 cm^{-1}.

b) Preparation of dimer 13 (AT-217).

(18)

Alloc removal

(13) AT-217

25

Tetrakis(triphenylphosphine)palladium (5 mg, 4 µmol) and
pyrrolidine (37 µL, 0.44 mmol) were added to a stirred solution
of **18** (190 mg, 0.2 mmol) and PPh₃ (6 mg, 0.02 mmol)in dry DCM
under a nitrogen atmosphere. After 30 s, the formation of a
white precipitate was observed. The reaction was allowed to stir
for 10 mins at which point TLC showed reaction completion. The
solvent was removed *in vacuo* to yield a white residue which was
purified by flash chromatography using gradient elution (from
2:98 to 5:95 v/v MeOH/CHCl₃). Evaporation of the pure fractions
yielded **13** (AT-217) (120 mg, 81%) as a white solid: ^{1}H NMR (400
MHz, CDCl₃) δ 7.68 (d, J = 4.07 Hz, 2H), 7.51 (s, 2H), 6.96 (br
s, 2H), 6.82 (s; 2H), 6.56 (s, 2H), 4.33-4.10 (m, 7H), 3.90-3.76
(m, 8H), 3.76-3.50 (m, 8H), 2.42-2.25 (m, 4H), 2.23-1.95 (m, 8H);
^{13}C NMR (100 MHz, CDCl₃) δ 164.5, 162.6, 161.8, 150.3, 147.5,
140.6, 130.7, 120.6, 111.5, 110.3, 68.8, 55.9, 53.7, 46.7, 38.1,
34.4, 29.6, 28.7, 24.2; MS (ES+) m/z (relative intensity) 740 ([M
+ H]$^{+\cdot}$, 100); IR (CHCl₃) 3320, 2951, 2237, 1656, 1622, 1600, 1534,
1505, 1463, 1432, 1383, 1340, 1262, 1216, 1092, 1019, 914, 874
cm^{-1}.

**Example 5: Synthesis of dimer 14 (AT-234)**

a) Preparation of 20.

Oxalyl chloride (227 µL, 2.6 mmol) was added to a stirred
solution of the diacid (**3**) (200 mg, 1.18 mmol) in anhydrous THF
(5 mL) at room temperature. The mixture was then treated with a
drop of DMF at which point vigorous effervescence occurred. The
mixture was allowed to stir until all effervescence had stopped.
This acid chloride solution was then added dropwise to a stirred
suspension of the hydrochloride salt of **19** (631 mg, 2.36 mmol, *J.
Med. Chem., 26, 1983, 1042-49*) and TEA (1.6 mL, 11.5 mmol) in

61

anhydrous THF (10 mL) at 0°C under a nitrogen atmosphere. The resulting white slurry was allowed to warm to room temperature and was stirred for 4 h. The solvent was then removed *in vacuo* and the residue was partitioned between CHCl₃ (100 mL) and aqueous 1N HCl (50 mL). The organic phase was washed with water, sat^d aqueous NaHCO₃, brine, dried (MgSO₄), filtered and evaporated *in vacuo* to give a white powder, which was shown to contain two components by TLC (EtOAc/Hexane). The major component (lower spot) was isolated by recrystallisation (CHCl₃/ diethyl ether) to provide **20** (160 mg , 23%): ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.14 (s, 2H), 7.51 (d, J =1.82 Hz, 2H), 7.47-7.30 (m, 10H), 6.97 (d, J = 1.90 Hz, 2H), 6.86 (s, 2H), 5.25 (s, 4H), 4.11 (s, 3H), 3.86 (s, 6H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 160.0, 158.1, 136.5, 130.1, 128.4, 127.9, 127.7, 122.6, 121.1, 118.6, 111.4, 108.7, 79.1, 64.9, 54.8, 36.2, 34.0; MS (ES$^+$) m/z (relative intensity) 616 ([M + Na]$^{+·}$, 60), 594.2 ([M + H]$^{+·}$, 40), 353 (100); IR (CHCl₃) 3266, 3121, 2953, 1710, 1638, 1585, 1545, 1438, 1390, 1333, 1258, 1194, 1150, 1109, 1109, 1086, 1029, 1005, 895, 873, 808, 781, 744, 694, 630, 609 cm^{-1}.

b) Preparation of 22.

A slurry of **20** (150 mg, 0.25 mmol) and 10% Pd/C (30 mg) in anhydrous DMF (5 mL) was hydrogenated at 30 PSI using Parr apparatus for 6 h at which point TLC showed reaction completion. The suspension was filtered through celite directly into a round

5   bottomed flask. The celite was quickly rinsed with anhydrous DMF (3 mL) and the combined filtrate was treated with HOBt (85 mg, 0.55 mmol) and EDCI (106 mg, 0.55 mmol) which resulted in the formation of a clear yellow solution that was stirred overnight. A sample of **10** (205 mg, 0.50 mmol) was then added and the

10 solution was allowed to stir for 24 h. The solution was then partitioned between CHCl$_3$ (100 mL) and 10% aqueous citric acid (100 mL) and the organic phase was washed with sat^d aqueous NaHCO$_3$, brine, dried (MgSO$_4$), filtered and the solvent was removed *in vacuo*. The residue was purified by column chromatography

15 (3:97 to 4:96 v/v MeOH/CHCl$_3$) to yield **22** (180 mg, 60%): ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.10 (s, 2H), 8.13 (t, J = 4.94 Hz, 2H), 7.22 (d, J =1.10 Hz, 2H), 7.10 (s, 2H), 6.90 (d, J = 1.16 Hz, 2H), 6.84 (s, 2H), 6.79 (s, 2H), 6.53 (broad s, 2H), 6.06-5.71 (m, 2H), 5.58-5.39 (m, 2H), 5.17-4.94 (m, 4H), 4.74-4.32 (m, 4H),

20 4.12 (s, 3H), 4.09-3.95 (m, 4H), 3.83 (m, 12H), 3.50 (m, 2H), 3.44-3.23 (m, 8H), 2.14-1.77 (m, 12H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 166.0, 161.3, 158.1, 154.4, 149.5, 148.0, 132.8, 130.2, 123.0, 121.7, 118.0, 116.9, 114.3, 111.2, 110.3, 104.2, 85.3, 79.1, 66.6, 60.5, 55.6, 45.9, 36.0, 35.60, 34.0, 29.0, 28.2, 22.7; MS

25 (ES$^+$) m/z (relative intensity) 1188 ([M + H]$^+$·, 100); IR (CHCl$_3$) 3320, 2928, 2246, 1709, 1627, 1535, 1513, 1464, 1435, 1409, 1312, 1277, 1218, 1134, 1104, 1054, 1014, 913, 871, 770, 731, 646 cm^{-1}.

*c) Preparation of dimer 14 (AT-234).*

63

A sample of **22** (150 mg, 0.126 mmol) was dissolved in an anhydrous mixture of $CHCl_3$ (10 mL) and acetonitrile (10 mL) under a
5   nitrogen atmosphere. PPh_3 (3 mg, 0.01 mmol), $Pd(PPh_3)_4$ (3 mg, 2.5 µmol), and pyrrolidine (22 µL, 0.26 mmol) were added simultaneously. Analysis by TLC showed reaction completion after 1 h. The solvent was removed *in vacuo* to yield a white residue which was purified by flash chromatography (gradient elution from
10   4:96 to 7:93 v/v $MeOH/CHCl_3$). Evaporation of the pure fractions yielded **14** (AT-234) (110 mg, 88%) as a white solid: ^1H NMR (400 MHz, DMSO-d_6) (diimine only) δ 10.1 (s, 2H), 8.12 (m, 2H), 7.78 (d, J = 4.4 Hz, 2H), 7.35 (s, 2H), 7.23 (s, 2H), 6.89 (s, 2H), 6.84 (s, 4H), 4.12 (s, 3H), 4.22-3.92 (m, 4H), 3.84 (2s, 12H),
15   3.65-3.56 (m, 2H), 3.40-3.20 (m, 8H), 2.37-2.17 (m, 4H), 2.07-1.85 (m, 8H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 164.2, 163.3, 161.3, 158.1, 150.3, 146.9, 140.5, 130.2, 123.1, 121.7, 119.7, 118.0, 111.2, 110.0, 104.2, 66.4, 55.6, 53.4, 48.5, 46.3, 35.9, 35.6, 34.0, 23.6; MS (ES^+) m/z (relative intensity) 984 ($[M + H]^{+\cdot}$,
20   100); IR ($CHCl_3$) 3316, 2952, 1632, 1602, 1530, 1436, 1387, 1264, 1217, 1199, 1090, 1066, 1010, 872, 664 cm^{-1}.

Example 6: Synthesis of acid capping unit 12

25   *a) (11S, 11aS)-7-Methoxy-8-(3-methoxycarbonyl-propoxy)-11-(tetrahydro-pyran-2-yloxy)-1,2,3,10,11,11a-hexahydro-5H-*

64

pyrrolo[2,1-c][1,4]benzodiazepine-10-carboxylic acid allyl ester
(41).

A solution of DHP (4.22 mL, 46.2 mmol) in EtOAc (30 mL) was
stirred for 10 min in the presence of a crystal of *p*-TSA
(catalytic quantity, 20 mg). A sample of **39** (2.0 g, 4.62 mmol)
was then added in one portion to this solution and the mixture
allowed to stir for 2 h. TLC analysis (EtOAc) revealed
completion of reaction and the solution was diluted with EtOAc
(70 mL) and washed with sat^d aqueous·NaHCO$_3$ (50 mL), brine (50
mL), dried (MgSO$_4$), filtered and the solvent was removed *in
vacuo*. The oily residue was further dried under strong vacuum to
remove any remaining DHP to provide **41** in quantitative yield
(2.38 g, 100%) which was used directly in the next step: ^{1}H NMR
(CDCl$_3$, 400 MHz) as a 4:5 mixture of diastereoisomers: δ 7.24-7.21
(2s, 2H), 6.88-6.60 (2s, 2H), 5.89-5.73 (m, 4H), 5.15-5.04 (m,
6H), 4.96-4.81 (m, 2H), 4.68-4.35 (m, 4H), 4.12-3.98 (m, 4H),
3.98-3.83 (m, 8H), 3.74-3.63 (m, 8H), 3.60-3.40 (m, 8H), 2.56-
2.50 (m, 4H), 2.23-1.93 (m, 12H), 1.92-1.68 (m, 10H), 1.66-1.48
(m, 20H); ^{13}C NMR (CDCl$_3$, 100 MHz) δ 173.4, 167.3, 149.2, 132.0,
114.5, 100.0, 98.5, 94.7, 91.8, 68.0, 67.8, 66.3, 64.0, 63.6,
63.4, 62.9, 56.1, 51.6, 51.6, 46.4, 46.3, 31.1, 30.9, 30.7, 30.4,
30.3, 29.1, 25.4, 25.3, 25.3, 24.2, 20.0, 19.8, 19.7; MS (ES$^+$)
m/z (relative intensity) 533 ([*M* + H]$^{+·}$, 100).

b) (11S, 11aS)-8-(3-Carboxy-propoxy)-7-methoxy-11-(tetrahydro-
pyran-2-yloxy)-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-
c][1,4]benzodiazepine-10-carboxylic acid allyl ester (12).

*100% ee*   (41)   *100% ee*   (12)

A solution of sodium hydroxide (340 mg, 8.5 mmol) in water (7 mL)
was added to a stirred solution of **41** (2.2 g, 4.26 mmol) in MeOH

5   (30 mL). The mixture was allowed to spin on the rotary
evaporator at 70°C for 15 min at atmospheric pressure, after
which time the reaction was found to be complete by TLC analysis.
The methanol was removed *in vacuo* and water (20 mL) was added.
The aqueous solution was then acidified to pH < 4 with 5% aqueous

10 citric acid solution. The resulting precipitate was then
extracted with EtOAc (100 mL) and the organic layer was washed
with brine (30 mL), dried (MgSO$_4$), filtered and the solvent was
removed *in vacuo*. Diethylether (50 mL) was added to the residue
and further evaporation *in vacuo* yielded **12** as a white foam (2.10

15 g, 98%): ^{1}H NMR (DMSO, 400 MHz) as a mixture of 4/5 of·
diastereoisomers δ 7.10 (2s, 2H), 6.90–6.84 (2s, 2H), 5.84–5.68
(m, 4H), 5.45–4.91 (m, 6H), 4.72–4.30 (m, 4H), 4.09–3.93 (m, 4H),
3.91–3.75 (m, 8H), 3.60–3.44 (m, 4H), 3.44–3.22 (m, 8H), 2.46–
2.33 (m, 4H), 2.20–1.76 (m, 14H), 1.76–1.31 (m, 12H); ^{13}C NMR

20 (DMSO, 100 MHz) δ 174.0, 173.9, 171.9, 166.2, 166.1, 149.7,
148.4, 148.3, 132.7, 116.6, 114.4, 110.5, 110.3, 99.2, 67.6,
67.4, 65.7, 65.5, 62.9, 59.5, 55.7, 45.9, 30.6, 30.3, 29.9, 29.8,
28.4, 28.3, 24.9, 24.8, 24.0, 23.8, 22.9, 22.8; MS (ES$^+$) *m/z*
(relative intensity) 519 ([*M* + H]$^{+·}$, 100). **12** was shown to be

25 optically pure at the C11a position by re-esterification (EDCI,
HOBt, then MeOH), THP removal (AcOH/THF/H$_2$O) followed by chiral
HPLC, as in Tercel *et al.*, *J. Med. Chem.*, 2003, 46, 2132–2151).

**Example 7: Synthesis of dimer 15 (AT-281)**

30

a) Preparation of 24

66

(23)   (24)

1-methyl-2-trichloroacetyl-4-nitropyrrole (**23**) (2 g, 7.36 mmol,
J. Am. Chem. Soc., 118, 1996, 6141-46) and 1,3-diaminopropane
(307 μL, 3.67 mmol) were dissolved in anhydrous THF (15 mL). The
5   formation of a precipitate was observed after 5 min and the
suspension was allowed to stir for 3 h. Following dilution with
diethyl ether (60 mL), the precipitate was collected by
filtration and dried *in vacuo* to yield **24** as an off-white fine
powder (1.28 g, 92%): ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.40 (t, J =
10 5.4 Hz, 2H), 8.12 (d, J = 1.51 Hz, 2H), 7.42 (d, J = 1.88 Hz,
2H), 3.92 (s, 6H), 3.26 (q, J = 6.49 Hz, 4H), 1.75 (p, J = 6.88
Hz, 2H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 159.8, 133.7, 127.7, 126.4,
107.2, 37.3, 36.5, 28.8; MS (ES$^+$) *m/z* (relative intensity) 379
([M + H]$^{+\cdot}$, 100); IR (CHCl$_3$) 3414, 3364, 3116, 2950, 1654, 550,
15 1530, 1501, 1418, 1346, 1311, 1264, 1222, 1209, 1139, 1111, 1075,
984, 950, 827, 849, 811, 747, 707 cm^{-1}.

b) Preparation of 25.

1) Hydrogenation

2) EDCl/ HOBt

(24)

(12)

(25)

20

A slurry of **24** (100 mg, 0.264 mmol) and 10% Pd/C (40 mg) in
anhydrous DMF (5 mL) was hydrogenated at 15 PSI using Parr
apparatus.   Completion of reaction was observed by TLC after 5 h.
The hydrogenation suspension was filtered through celite directly
5   into a round-bottomed flask containing a pre-prepared (stirred
for 3 h) solution of **12** (265mg, 0.528 mmol), EDCI (152 mg, 0.792
mmol) and HOBt (121 mg, 0.790 mmol) in anhydrous DMF (4 mL).   The
reaction mixture was stirred at 60°C for a further 3 h and then
overnight at room temperature.   The following day the mixture was
10   diluted with $CHCl_3$ (200 mL) and washed with water (200 mL), 10%
aqueous citric acid (100 mL), sat^d aqueous $NaHCO_3$ (100 mL), brine
(100 mL), dried ($MgSO_4$), filtered and the solvent was removed *in
vacuo*.   The residue was purified by flash chromatography
(gradient elution from 1:99 to 3:97 v/v $MeOH/CHCl_3$) to yield **25**
15   as an off-white solid (190 mg, 54.5%): ^1H NMR (400 MHz, DMSO-d_6) δ
9.82 (s, 2H), 8.00 (t, J = 5.44 Hz, 2H), 7.12 (m, 4H), 6.93 (m,
1H), 6.83 (s, 1H), 6.67 (m, 2H), 5.79-5.68 (m, 4H), 5.88-5.58 (m,
6H), 4.70-4.31 (m, 4H), 4.06-3.96 (m, 4H), 3.79 (pseudo d, 14H),
3.58-3.46 (m, 4H), 3.35 (m, 4H), 3.20 (q, J = 6.41 Hz, 4H), 2.40
20   (t, J = 7 Hz, 4H), 2.19-1.77 (m, 12H), 1.65 (m, 6H), 1.55-1.28
(m, 8H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 168.7, 168.6, 166.2, 166.1,
161.2, 148.4, 148.2, 132.7, 122.9, 121.9, 117.5, 116.6, 114.4,
110.3, 103.2, 79.1, 68.0, 67.8, 65.5, 64.9, 62.8, 59.4, 55.7,
45.9, 36.1, 35.9, 31.7, 31.6, 30.6, 30.3, 29.7, 28.4, 28.3, 24.9,
25   24.7, 24.6, 24.4; MS (ES^+) m/z (relative intensity) 1320 ([M +
$H]^{+\cdot}$, 100).

*c) Preparation of 15 (AT-281).*

68

(25)

Cleave Alloc

(15) AT-281

A stirred solution of **25** (138 mg, 0.104 mmol) in anhydrous $CHCl_3$
(5 mL) was treated with Pd(PPh$_3$)$_4$ (2.4 mg, 2.1 μmol) and
5   pyrrolidine (19.2 μL, 0.246 mmol). After 1 h stirring at room
temp reaction completion was observed by TLC analysis. The
solvent was removed *in vacuo* and the residue purified by flash
chromatography (gradient from 3:97 to 7:93 v/v MeOH/CHCl$_3$) to
yield **15** (AT-281) as an off-white solid (99mg, 90%). A sample
10   was dissolved in deuterated DMSO and NMR data of the diimine form
was recorded after at least 48 h standing at room temperature:
^{1}H NMR (400 MHz, DMSO-d_6) δ 9.83 (s, 2H), 8.01 (t, J = 5.73 Hz,
2H), 7.79 (d, J = 4.4 Hz, 2H), 7.35 (s, 2H), 7.12 (s, 2H), 6.83
(s, 2H), 6.69 (s, 2H), 4.20-3.99 (m, 4H), 3.82 (m, 12H), 3.75-
15   3.58 (m, 4H), 3.47-3.40 (m, 2H), 3.22 (m, 4H), 2.43 (t, J = 7.3
Hz, 4H), 2.33-2.15 (m, 4H), 2.12-1.94 (m, 8H), 1.67 (m, 2H); ^{13}C
NMR (100 MHz, DMSO-d_6) δ 168.7, 164.2, 163.3, 161.2, 150.2,
146.9, 140.6, 122.9, 121.9, 119.8, 117.5, 111.3, 110.1, 103.3,
79.1, 67.8, 56.0, 55.6, 53.4, 46.3, 36.1, 35.9, 31.8, 29.7, 28.8,
20   24.7, 23.6, 18.5; MS (ES$^+$) m/z (relative intensity) 947 ([M +
H]$^{+·}$, 100).

Example 8: Synthesis of dimer 16 (AT-242)

a) Preparation of 26.

A slurry of **24** (200 mg, 0.53 mmol) and 10% Pd/C (50 mg) in
anhydrous DMF (7 mL) was hydrogenated at 15 PSI using Parr
apparatus. Completion of the reaction was observed by TLC after
6 h. The suspension was filtered through celite directly into a
round-bottomed flask containing **42** (377 mg, 1.06 mmol, *J. Am.
Chem. Soc., 118, 1996, 6141-46*). The reaction mixture was
stirred at 60°C for 1 h and then overnight at room temperature.
The following day the mixture was extracted with chloroform (200
mL), washed with water (200 mL), 10% aqueous citric acid (100
mL), sat^d aqueous $NaHCO_3$ (100 mL), brine (100 mL), dried ($MgSO_4$),
filtered and the solvent was removed *in vacuo*. The residue was
purified by flash chromatography (3.5:96.5 v/v MeOH/CHCl$_3$) to
yield **26** as an off-white solid (284 mg, 70%): ^{1}H NMR (400 MHz,
DMSO-d_6) δ 9.83 (s, 2H), 9.09 (s, 2H), 8.03 (t, J = 5.6 Hz, 2H),
7.19 (d, J = 1.37 Hz, 2H), 6.89 (s, 4H), 6.84 (s, 2H), 3.82 (s,
12H), 3.24 (q, J = 6.16 Hz, 4H), 1.71 (p, J = 6.70 Hz, 2H), 1.47
(s, 18H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 161.3, 158.3, 152.8, 122.9,
122.8, 122.3, 122.1, 117.7, 117.0, 104.1, 103.7, 36.0, 35.9,
29.7, 28.2; MS (ES$^+$) m/z (relative intensity) 763 ([M + H]$^{+\cdot}$,
100); IR (CHCl$_3$) 3311, 2977, 1697, 1643, 1586, 1529, 1434, 1402,
1364, 1248, 1206, 1161, 1098, 1063, 997, 895, 804, 757, 664 cm^{-1}.

70

b) *Preparation of 27.*

(26)

cleave BOC then
couple (11)

Finely ground **26** (200 mg, 0.262 mmol) was treated with 4N HCl in
dioxane (10 mL) and the mixture vigorously stirred. After a
short time, the formation of a white precipitate was observed.
The mixture was allowed to stir for a further 45 min and the
solvent was removed *in vacuo*. This salt was suspended in
anhydrous THF (7 mL) in the presence of DIPEA (0.45 mL, 2.59
mmol) and treated dropwise with a pre-prepared (stirred for 10
min) mixture of **11** (235 mg, 0.532 mmol), oxalyl chloride (65 μL,
0.549 mmol) and DMF (1 drop) in anhydrous THF (8 mL). Further
anhydrous DMF (5 mL) was then added and the suspension became a
solution. After 1 h stirring, completion of the reaction was
observed by TLC and the solvent was removed *in vacuo*. The
residue was dissolved in $CHCl_3$, washed with water (200 mL), 10%
aqueous citric acid (100 mL), sat^d aqueous $NaHCO_3$ (100 mL), brine
(100 mL), dried ($MgSO_4$), filtered and the solvent was removed *in*
vacuo. The residue was purified by flash chromatography
(gradient elution from neat $CHCl_3$ to 4:96 v/v MeOH/) to give **27**
as an off-white solid (217 mg, 58%): ^{1}H NMR (400 MHz, DMSO-d_6) δ
9.88-9.86 (m, 4H), 8.04 (t, J = 5.6 Hz, 2H), 7.20-7.18 (m, 4H),
7.11 (s, 2H), 6.89 (m, 6H), 5.79 (m, 2H), 5.36 (d, J = 9 Hz, 2H),
5.04 (m, 4H), 4.58-4.44 (m, 4H), 4.04 (m, 4H), 3.83 (s, 18H),3.47
(s, 8H), 3.33 (m, 4H), 3.24 (q, J = 6.10 Hz, 4H), 2.45 (t, J =
7.15 Hz, 4H), 2.06 (m, 6H), 1.97-1.85 (m, 6H), 1.71 (p, J = 6.56
Hz, 2H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 168.8, 166.1, 161.3, 158.3,

71

149.7, 148.3, 132.1, 128.4, 122.9, 122.7, 122.0, 122.0, 118.1,
117.8, 114.4, 110.4, 104.0, 103.8, 92.9, 79.1, 68.1, 55.6, 45.9,
36.0, 35.9, 31.7, 28.4, 22.8; MS (ES$^+$) m/z (relative intensity)
1424 ([M + H]$^{+\cdot}$, 60), 681 (100); IR (CHCl$_3$) 3311, 2977, 1697,
1643, 1586, 1529, 1434, 1402, 1364, 1248, 1206, 1161, 1098, 1063,
997, 895, 804, 757, 664 cm^{-1}.

c) Preparation of dimer 16 (AT-242).

(27)

Cleave Alloc

(16) AT-242

A stirred solution of **27** (167 mg, 0.117 mmol) in anhydrous CHCl$_3$
(5 mL) was treated with Pd(PPh$_3$)$_4$ (2.7 mg, 2.3 μmol) and
pyrrolidine (20.6 μL, 0.246 mmol). After stirring at room
temperature for 1 h reaction completion was observed by TLC. The
solvent was removed *in vacuo* and the residue purified by flash
chromatography (gradient elution from 4:96 to 8:92 v/v
MeOH/CHCl$_3$) to yield **16** (AT-242) as an off-white solid (123 mg,
88%). A sample was dissolved in deuterated DMSO and NMR data of
the diimine form was recorded after standing for at least 48 h:
^{1}H NMR (400 MHz, DMSO-d_6) (diimine only) δ 9.88 (m, 4H), 8.04 (t,
J = 5.4 Hz, 2H), 7.79 (d, J = 4.4 Hz, 2H), 7.35 (s, 2H), 7.20-
7.18 (m, 4H), 6.88 (s, 4H), 6.84 (s, 2H), 4.15-4.04 (m, 4H), 3.84
(m, 18H), 3.70-3.58 (m, 4H), 3.43-3.36 (m, 2H), 3.24 (m, 4H),
2.45 (t, J = 7.3 Hz, 4H), 2.29-2.24 (m, 4H), 2.09-1.94 (m, 8H),
1.69 (m, 2H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 168.8, 164.2, 163.3,
161.3, 158.3, 150.2, 146.9, 140.5, 122.9, 122.7, 122.0, 121.9,

72

119.8, 118.1, 117.8, 111.2, 110.1, 104.0, 103.9, 67.8, 55.6, 53.4, 46.3, 36.0, 35.9, 31.9, 29.7, 28.8, 24.7, 23.6; MS (ES$^+$) m/z (relative intensity) 1197 ($[M + H]^{+\cdot}$, 100); $[\alpha]^{25}_D$ = +315° (c = 0.45, CHCl$_3$); IR (CHCl$_3$) 3295, 2947, 1639, 1597, 1532, 1508, 1434,
5   1405, 1341, 1263, 1215, 1155, 1095, 1016, 752, 664 cm^{-1}.

Example 9: Synthesis of 17 (AT-288).

a) Preparation of 30.


(28)

(29)

1) EDCI / HOBt

2) H$_2$N⌒⌒NH$_2$

(30)

10

A solution of **29** (450 mg, 0.92 mmol, *J. Am. Chem. Soc., 122, 2000, 6382-94*) in anhydrous DMF (6 mL) was treated with EDCI (195 mg, 1.02 mmol) and HOBt (155.2 mg, 1.02 mmol) and stirred for 5 h. 1,3-diaminopropane (42.2 µl, 0.50 mmol) was then added and the
15   resulting mixture was allowed to stir overnight. The following day, completion of reaction was observed by TLC and the mixture was diluted with CHCl$_3$ (100 mL), washed with 5% aqueous citric acid (50 mL), water (50 mL), sat^d aqueous NaHCO$_3$ (50 mL), brine (50 mL) and dried (MgSO$_4$). The mixture was filtered and solvent
20   removed *in vacuo* to provide a yellow oil which was triturated with diethylether and the solvent was decanted off. The supernatant was removed and the residue was dried *in vacuo* to yield **30** as an off-white powder (400 mg, 86%): ^{1}H NMR (400 MHz,

DMSO-*d₆*) δ 9.86 (m, 4H), 9.08 (s, 2H), 8.05 (t, *J* = 5.61 Hz, 2H), 7.23 (m, 4H), 7.06 (s, 2H), 6.90 (m, 6H), 3.86 (m, 18H), 3.26 (q, *J* = 6.35 Hz, 4H), 1.71 (m, 2H), 1.47 (s, 18H); ^{13}C NMR (100 MHz, DMSO-*d₆*) δ 162.3, 161.3, 158.5, 158.4, 152.8, 122.9, 122.8, 122.7, 122.3, 122.2, 118.3, 117.8, 117.0, 104.7, 104.1, 103.8, 78.2, 64.9, 36.0, 36.0, 35.9, 35.7, 30.7, 29.7, 28.2, 15.1; MS (ES⁺) *m/z* (relative intensity) 1007 ([*M* + H]⁺·, 7), 833 (100).

b) Preparation of 31.

(30)

1) 4N HCl in dioxane

(12)

EDCI / HOBT/ DIPEA

(31)

A solution of acid capping unit **12** (300 mg, 0.597 mmol) in anhydrous DMF (5 mL) was treated with EDCI (126 mg, 0.656 mmol) and HOBt (100 mg, 0.653 mmol) and allowed to stir for 3 h. Finely ground **30** (300 mg, 0.298 mmol) was suspended in 4N HCl-dioxane (10 mL). Following stirring for 1 h the mixture was subjected to ultrasound for 3 min and the volatiles were removed *in vacuo* to provide a grey solid. This was then dissolved in anhydrous DMF (5 mL) and DIPEA (0.5 mL, 2.87 mmol) and treated dropwise with the aforementioned activated acid solution. The resulting mixture was stirred at 60°C for 1 h and then overnight at room temperature. The following day, completion of reaction

74

was observed by TLC and the mixture was diluted with $CHCl_3$ (100 mL), washed with 5% aqueous citric acid (50 mL), water (50 mL), sat^d aqueous $NaHCO_3$ (50 mL), brine (50 mL), dried ($MgSO_4$), filtered and the solvent removed *in vacuo* to provide a yellow oil. The residue was triturated with diethylether and decanted. The supernatant was removed and the residue was dried *in vacuo* to furnish a tan solid which was purified by flash chromatography (gradient elution from neat $CHCl_3$ to 4:96 v/v $MeOH/CHCl_3$) to yield pure **31** (250 mg, 46%): ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.89 (m, 6H), 8.06 (t, J = 5.55 Hz, 2H), 7.21 (m, 6H), 7.10 (m, 4H), 6.89 (m, 6H), 5.75 (m, 4H), 5.18-4.92 (m, 6H), 4.69-4.32 (m, 4H), 4.01 (m, 4H), 3.86 (m, 26H), 3.50 (m, 4H), 3.40 (m, 4H), 3.26 (q, J = 6.34 Hz, 4H), 2.44 (t, J = 7.04 Hz, 4H), 2.18-1.77 (m, 12H), 1.76-1.56 (m, 6H), 1.56-1.30 (m, 8H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 168.8, 166.2, 161.3, 158.4, 158.4, 148.4, 148.2, 132.7, 122.9, 122.7, 122.7, 122.2, 122.1, 122.0, 118.4, 118.1, 117.8, 114.4, 104.7, 104.1, 103.8, 79.1, 68.0, 64.9, 55.7, 45.9, 40.1, 36.0, 35.9, 31.8, 30.3, 29.7, 28.4, 28.3, 24.9, 24.7, 24.4, 22.9, 19.3, 15.1.

c) *Preparation of dimer 17 (AT-288)*.

(31)

Alloc cleavage

(17)

A solution of **31** (200 mg, 0.111 mmol) in anhydrous $CHCl_3$ (6 mL) was treated with Pd(PPh_3)$_4$ (2.5 mg, 2.1 μmol) and pyrrolidine

(19.5 µL, 0.233 mmol). After stirring for 2 h completion of reaction was observed by TLC. The solvent was removed *in vacuo* and the residue purified by flash chromatography (gradient elution from 4:96 to 9:91 v/v MeOH/CHCl$_3$) to yield **17** (AT-288) as an off-white solid (123 mg, 77%). A sample was dissolved in deuterated DMSO and NMR data of the diimine form was recorded after standing for at least 48 h: ^{1}H NMR (400 MHz, DMSO-d_6) (diimine only) δ 9.89 (m, 6H), 8.04 (pseudo triplet, 2H), 7.79 (d, J = 4.4 Hz, 2H), 7.35 (s, 2H), 7.25 (s, 2H), 7.21 (s, 2H), 7.18 (s, 2H), 7.05 (s, 2H), 6.90 (s, 4H), 6.84 (s, 2H), 4.15-4.04 (m, 4H), 3.84 (m, 24H), 3.72-3.58 (m, 4H), 3.41-3.37 (m, 2H), 3.24 (m, 4H), 2.45 (t, J = 7.3 Hz, 4H), 2.30-2.24 (m, 4H, C1), 2.12-1.90 (m, 8H), 1.70 (m, 2H); ^{13}C NMR (100 MHz, DMSO) δ 168.8, 164.2, 163.3, 161.3, 158.4, 158.4, 151.2, 146.9, 140.6, 122.9, 122.7, 122.7, 122.2, 122.1, 122.0, 119.8, 118.4, 118.1, 117.8, 111.3, 110.2, 104.7, 104.1, 104.0, 79.1, 67.8, 55.6, 53.4, 48.6, 46.3, 36.0, 35.9, 31.9, 28.8, 24.7, 23.6, 22.6; MS (ES$^+$) *m/z* (relative intensity) 1435 ([*M* + H]$^{+\cdot}$, 35), 718 (100).

Example 10: Synthesis of acid capping unit (11)

a) (11S, 11aS)-7,11-Dimethoxy-8-(3-methoxycarbonyl-propoxy)-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carboxylic acid allyl ester (40).

(39)   Methylation   80% ee   (40)

A solution of **39** (1.2 g, 2.77 mmol) in anhydrous DCM (50 mL) was treated with MeI (1.72 mL, 27.6 mmol) and silver (I) oxide (2.5g, 10.8 mmol) and the suspension was heated at reflux for 24 h. The reaction was then found to be complete as judged by TLC (EtOAc). The suspension was filtered through celite and the volatiles were removed *in vacuo* (caution: MeI is carcinogenic, evaporate in a

76

fumehood) to yield the methyl ether **40** (1.27 g, 99%): Chiral HPLC revealed **40** to be a mixture of two enantiomers in a 90:10 ratio (90% of the C11aS isomer, 10% of the C11aR isomer); ^{1}H NMR (CDCl$_3$, 400 MHz) δ 7.22 (s, 1H), 6.65 (s, 1H), 5.86-5.65 (m, 1H), 5.43 (d, J = 9.09 Hz, 1H), 5.18-4.94 (m, 2H), 4.71-4.32 (m, 2H), 4.07 (t, J = 6.21 Hz, 2H), 3.89 (s, 3H), 3.66 (m, 4H), 3.47 (m, 4H), 3.40 (m, 1H), 2.54 (t, J = 7.19 Hz, 2H), 2.14 (p, J = 6.57 Hz, 2H), 2.09-1.91 (m, 4H); ^{13}C NMR (CDCl$_3$, 100 MHz) δ 173.4, 167.2, 156.2, 150.1, 149.1, 132.0, 128.6, 126.8, 117.2, 114.4, 110.9, 93.3, 68.0, 66.4, 60.1, 56.5, 56.1, 51.6, 46.3, 30.3, 29.0, 24.2, 23.2; MS (ES$^+$) m/z (relative intensity) 463 ([M + H]$^+$·, 100).

b) (11S, 11aS)-8-(3-Carboxy-propoxy)-7,11-dimethoxy-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carboxylic acid allyl ester (11).

80% ee   (40)   *80% ee*   (11)

A solution of sodium hydroxide (207 mg, 5.19 mmol) in water (5 mL) was added to a stirred solution of **40** (1.2 g, 2.59 mmol) in MeOH (20 mL). The mixture was allowed to spin on a rotary evaporator at 70°C for 15 min at atmospheric pressure after which time the reaction was found to be complete as judged by TLC (90:10:1 v/v EtOAc/MeOH/AcOH,). The methanol was removed *in vacuo* and water (20 mL) was added. 'The aqueous solution was acidified to pH < 3 with 1N aqueous HCl and extracted with EtOAc (2 x 50 mL). The organic layers were combined, washed with brine (30 mL), dried (MgSO$_4$), filtered and the solvent was removed *in vacuo*. Diethylether (50 mL) was added to the residue and further evaporation *in vacuo* yielded **11** as a white foam (1.15 g, 99%): ^{1}H NMR (DMSO-d_6, 400 MHz) δ 7.24 (s, 1H), 6.65 (s, 1H), 5.85-5.66 (m, 1H), 5.43 (d, J = 9.01 Hz, 1H), 5.17-4.95 (m, 2H), 4.68-4.34 (m, 2H), 4.09 (t, J = 6.95 Hz, 2H), 3.89 (s, 3H), 3.74-3.61 (m, 1H),

3.59-3.46 (m, 4H), 3.46-3.35 (m, 1H), 2.59 (t, J = 7.15 Hz, 2H),
2.16 (quint, J = 6.58 Hz, 2H), 2.10-1.89 (m, 4H); ^{13}C NMR (DMSO,
100 MHz) δ 177.8, 176.3, 167.4, 156.1, 150.2, 149.2, 131.9,
128.6, 126.7, 117.3, 114.4, 110.9, 93.4, 67.9, 66.5, 60.4, 60.2,
56.5, 56.1, 46.4, 30.2, 28.9, 24.0, 23.2, 21.0; MS (ES$^+$) m/z
(relative intensity) 449 ([M + H]$^{+\cdot}$, 100); IR (CHCl$_3$) 2942, 1712,
1603, 1516, 1467, 1436, 1408, 1314, 1275, 1205, 1111, 1087, 1040,
972, 918, 767, 731 cm^{-1}.

Example 11: Synthesis of dimer 18 (AT-235)

a) Preparation of 32.

coupling step 1.
with compound (10)

(29)

(32)

A solution of **29** (197 mg, 0.404 mmol) in anhydrous DMF (5 mL) was
treated with EDCI (81 mg, 0.422 mmol) and HOBt (65 mg, 0.425
mmol) and was stirred for 7 h. A solution of the amine capping
unit (**10**) (164 mg, 0.404 mmol) in anhydrous DMF (5 mL) was then
added and the resulting mixture was allowed to stir overnight at
room temperature. The mixture was diluted with CHCl$_3$ (200 mL),
washed with 5% aqueous citric acid (100 mL), water (100 mL), sat^d
aqueous NaHCO$_3$ (100 mL), brine (100 mL), dried (MgSO$_4$), filtered
and the solvents were removed *in vacuo* to provide a yellow oil
Purification by flash chromatography (1:99 v/v MeOH/CHCl$_3$)

yielded **32** (250 mg, 71%): ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.88 (m,
2H), 9.09 (s, 1H), 8.09 (t, J = 5.24 Hz), 7.20 (m, 2H), 7.10 (s,
1H), 7.05 (d, J = 1.35 Hz, 1H), 6.90 (s, 1H), 6.85 (s, 1H), 6.79
(s, 1H), 6.53 (br s, 1H), 5.89-5.71 (m, 1H), 5.48 (m, 1H), 5.16-
4.97 (m, 2H), 4.73-4.32 (m, 2H), 4.02 (m, 2H), 3.83 (m, 12H),
3.51 (m, 1H), 3.35 (m, 4H), 2.13-1.79 (m, 6H), 1.47 (s, 9H); ^{13}C
NMR (100 MHz, DMSO-d_6) δ 166.0, 161.4, 158.4, 158.4, 154.4,
152.8, 149.4, 147.9, 132.8, 128.5, 122.8, 122.6, 122.3, 122.1,
122.1, 118.3, 117.8, 117.0, 114.2, 110.2, 104.6, 104.2, 103.7,
85.3, 79.1, 78.2, 66.6, 65.5, 60.5, 55.6, 45.9, 36.0, 35.9, 35.6,
29.0, 28.2, 22.7; IR (CHCl$_3$) 3315, 2976, 1698, 1633, 1587, 1515,
1465, 1435, 1405, 1314, 1269, 1206, 1163, 1105, 1061, 996, 754
cm^{-1}; MS (ES$^+$) m/z (relative intensity) 872 ([M + H]$^{+\cdot}$,100).

b) Preparation of 33.

(32)

BOC cleavage
coupling step 2
with compound (11)

(33)

Finely ground **32** (180 mg, 0.206 mmol) was treated with a solution
of 4N HCl in dioxane (8 mL) and stirred. After 1 h the solvent
was evaporated *in vacuo* to provide a grey coloured salt which was
dissolved in anhydrous THF (5 mL) in the presence of DIPEA (180
μL, 1.035 mmol). This mixture was treated dropwise with a pre-

79

prepared (5 min stirring) solution of acid capping unit **11** (93 mg, 0.207 mmol), oxalyl chloride (27 μL, 0.228 mmol) and DMF (1 drop) in anhydrous THF (5 mL) at 0°C (ice/acetone bath). After stirring for 1 h, the THF was removed *in vacuo* and residue

5   dissolved in CHCl$_3$ (100 mL). The organic phase was washed with 5% aqueous citric acid (50 mL), water (50 mL), sat^d aqueous NaHCO$_3$ (50 mL), brine (50 mL) dried (MgSO$_4$), filtered and the solvent removed *in vacuo* to provide a yellow oil. Purification by flash chromatography (gradient elution from 3:97 to 4:96 v/v

10   MeOH/CHCl$_3$) yielded **33** (110 mg, 44%): ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.89 (s, 3H), 8.09 (m, 1H), 7.25 (d, J = 1.36 Hz, 1H), 7.19 (m, 2H), 7.11 (m, 2H), 7.05 (s, 1H), 6.92 (m, 3H), 6.79 (s, 1H), 6.53 (br s, 1H), 6.02-5.70 (m, 2H), 5.49 (m, 1H), 5.37 (d, J = 8.8 Hz, 1H), 5.14-4.95 (m, 4H), 4.72-4.32 (m, 4H), 4.04 (m, 4H), 3.85 (m,

15   15H), 3.47 (m, 5H), 3.40-3.20 (m, 6H), 2.45 (t, J = 7.04 Hz, 2H), 2.14-1.80 (m, 12H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 168.8, 166.1, 161.3, 158.4, 154.4, 148.3, 122.8, 122.7, 122.7, 122.1, 122.0, 118.1, 114.3, 104.6, 104.2, 92.9, 79.1, 55.6, 45.9, 36.0, 35.9, 22.8; MS (ES$^+$) m/z (relative intensity) 1202 ([M + H]$^{+\cdot}$, 40), 292

20   (100).

c) Preparation of dimer 18 (AT-235).

(33)

Alloc cleavage

(18) AT-235

A solution of **33** (80 mg, 0.067 mmol) in anhydrous $CHCl_3$ (5 mL) was treated with $Pd(PPh_3)_4$ (1.5 mg, 1µmol) and pyrrolidine (11.7

5   µL, 0.140 mmol) and stirred. After 1 h stirring at room temperature reaction completion was observed by TLC. The solvent was removed *in vacuo* and the residue purified by flash chromatography (gradient elution from 5:95 to 7:93 v/v $MeOH/CHCl_3$) to yield **18** (AT-235) as an off-white solid (56 mg,

10   85%). A sample was dissolved in deuterated DMSO and NMR data of the diimine form was recorded after standing for at least 48 h: ^{1}H NMR (400 MHz, DMSO-d_6) (diimine only) δ 9.90 (s, 3H), 8.10 (m, 1H), 7.79 (d, 2H, J = 4.36 Hz), 7.35 (s, 2H), 7.25 (s,1H), 7.20 (2s, 2H), 7.05 (s, 1H), 6.90 (s, 2H), 6.84 (s, 2H), 4.21-4.01 (m,

15   4H), 3.85-3.81 (m, 15H), 3.61 (m, 2H), 3.46-3.35 (m, 6H), 2.45 (m, 2H), 2.38-2.17 (m, 4H), 2.13-1.89 (m, 8H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 168.8, 164.2, 158.4, 150.3, 150.2, 146.9, 140.5, 122.7, 122.1, 122.0, 119.7, 118.4, 118.4, 117.8, 114.9, 111.2, 110.1, 104.6, 104.2, 103.9, 67.8, 66.4, 55.8, 55.6, 53.7, 53.4,

20   48.5, 46.3, 36.0, 35.9, 35.6, 30.2, 29.0, 28.8, 24.7, 23.6, 22.4; MS (ES$^+$) m/z (relative intensity) 984 ([M + H]$^{+\cdot}$, 100); IR (CHCl$_3$)

3306, 2949, 1638, 1597, 1555, 1508, 1465, 1435, 1405, 1262, 1216, 1090, 1064 cm^{-1}.

Example 12: Synthesis of dimer 49 (SJG-085)

a) Alternative method for the preparation of compound 26

EDCI (671 mg, 3.50 mmol) was added to a stirred solution of the acid **43** (1.15 g, 3.18 mmol) in anhydrous DMF (12 mL) at room temperature. After 5 min stirring at room temperature, the reaction mixture was treated with HOBt (473 mg, 3.50 mmol) and allowed to stir under a nitrogen atmosphere for 3 h at which point TLC (EtOAc) revealed reaction completion and the formation of the desired benzotriazole (Bt) ester **44**. The reaction mixture was treated with 1,3-diaminopropane (133 µL, 118 mg, 1.59 mmol) and allowed to continue stirring under nitrogen for 16 h. Following dilution with H$_2$O (600 mL), the mixture was extracted with CHCl$_3$ (120 mL). The organic layer was washed with 1% aqueous citric acid (40 mL), saturated aqueous NaHCO$_3$ (40 mL), brine (40 mL), dried (MgSO$_4$), filtered and evaporated to provide the crude product. Purification by flash chromatography (EtOAc) provided the pure tetrapyrrole **26** as an orange oil (862 mg, 71%): LC/MS 3.38 min (ES+) *m/z* (relative intensity) 763 ([*M* + H]$^{+\cdot}$, 100), 663 (22), 301 (49), 143 (29).

82

b) *Preparation of 45.*

26

45

A solution of 4M HCl in dioxane (10 mL) was added to the bis-Boc
protected tetrapyrrole **26** (862 mg, 1.13 mmol). The reaction
failed to stir, however, the addition of THF (3 mL) assisted
mobility. The slurry was allowed to stir at room temperature
under a nitrogen atmosphere for 1 h, at which point TLC (EtOAc)
revealed complete consumption of starting material. The solvent
was removed by evaporation *in vacuo* to provide the pyrrole amine
HCl salt **26a** as a solid which was analysed by LC/MS (0.62 and
1.38 min gave identical spectra (ES+) *m/z* (relative intensity)
563 ([M + H]$^{+\cdot}$, 100), 282 (19), 245 (50), 219 (30), 123 (52)) and
carried through to the next step without further purification.
In a separate vessel, EDCI (477 mg, 2.49 mmol) was added to a
stirred solution of Boc-β-Ala-OH (428 mg, 2.26 mmol) in anhydrous
DMF (6 mL) at room temperature. After 10 min stirring at room
temperature, the reaction mixture was treated with HOBt (336 mg,
2.49 mmol) and allowed to stir under a nitrogen atmosphere for 3
h. The Boc-β-Ala-OBt ester solution was added to the pyrrole
amine HCl salt **26a** in the presence of DIPEA (0.434 mL, 0.322 g,
2.49 mmol) and the reaction mixture was allowed to stir under a
nitrogen atmosphere. After 16 h stirring LC/MS (2.95 min (ES+)
m/z (relative intensity) 905 ([M + H]$^{+\cdot}$, 71), 805 (23), 372 (100))

revealed formation of the desired product. Following dilution with H$_2$O (600 mL), the mixture was extracted with CHCl$_3$ (105 mL). The organic layer was washed with 1% aqueous citric acid (40 mL), saturated aqueous NaHCO$_3$ (40 mL), brine (40 mL), dried (MgSO$_4$), filtered and evaporated to provide the pure product **45** (812 mg, 79%): ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.89 (s, 2H), 9.88 (s, 2H), 8.06 (t, 2H, J = 5.7 Hz), 7.21 (d, 2H, J = 1.6 Hz), 7.18 (d, 2H, J = 1.5 Hz), 6.89-6.83 (m, 6H), 3.84 (s, 6H), 3.83 (s, 6H), 3.30-3.12 (m, 8H), 2.41 (t, 4H, J = 7.3 Hz), 1.70 (p, 2H, J = 6.6 Hz), 1.40 (s, 18H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 167.5, 161.3, 158.3, 155.5, 122.9, 122.7, 122.0, 121.9, 118.1, 117.8, 104.0, 103.8, 77.6, 36.7, 36.1, 36.0, 35.9, 29.7, 28.2; IR (ATR) 3298, 2930, 1650, 1579, 1518, 1463, 1433, 1386, 1365, 1252, 1206, 1164, 1095, 1062, 1005, 973, 775, 660 cm^{-1}.

c) Preparation of 46.

45

46 R = Boc
47 R = H.HCl

A solution of 4M HCl in dioxane (10 mL) was added to a stirred solution of the bis-Boc protected compound **45** (800 mg, 0.89 mmol) in THF (3 mL). The slurry was allowed to stir at room temperature under a nitrogen atmosphere for 1 h, at which point TLC (90:10 v/v CHCl$_3$/MeOH) revealed complete consumption of starting material. The solvent was removed by evaporation *in vacuo* to provide the pyrrole amine HCl salt **45a** as a solid which

84

was analysed by LC/MS (0.62 and 1.47 min gave identical spectra (ES+) m/z (relative intensity) 705 ([M + H]$^{+\cdot}$, 15), 512 (10), 416 (30), 390 (43), 353 (80), 316 (48), 290 (82), 245 (38), 194 (100)) and carried through to the next step without further purification. In a separate vessel, EDCI (374 mg, 1.95 mmol) was added to a stirred solution of dipyrrole **43** (641 mg, 1.77 mmol) in anhydrous DMF (6 mL) at room temperature. After 5 min stirring at room temperature, the reaction mixture was treated with HOBt (263 mg, 1.95 mmol) and allowed to stir under a nitrogen atmosphere for 2.5 h at which point TLC (90:10 v/v CHCl$_3$/MeOH) revealed reaction completion and the formation of the desired benzotriazole (Bt) ester **44**. The solution containing **44** was added to the pyrrole amine HCl salt **45a** in the presence of DIPEA (0.337 mL, 0.252 g, 1.95 mmol) and the reaction mixture was allowed to stir under a nitrogen atmosphere. After 16 h stirring LC/MS (3.15 min (ES+) m/z (relative intensity) 1394 ([M + 2H]$^{+\cdot}$, 4), 716 (6), 597 (22), 143 (100)) and TLC (90:10 v/v CHCl$_3$/MeOH) revealed formation of the desired product. The reaction mixture was poured into H$_2$O (600 mL) which resulted in the formation of an orange precipitate which was collected by vacuum filtration and dried in the vacuum desicator to provide the crude product (922 mg). Purification by flash chromatography (gradient elution: 95:5 v/v CHCl$_3$/MeOH to 90:10 v/v CHCl$_3$/MeOH) provided the pure Boc-protected octapyrrole **46** as a solid (243 mg, 20%): ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.93 (s, 2H), 9.90 (s, 2H), 9.84 (s, 2H), 9.11 (s, 2H), 8.08-8.06 (m, 4H), 7.25-7.16 (m, 6H), 6.90-6.79 (m, 10H), 3.85 (s, 6H), 3.82 (s x 2, 12H), 3.81 (s, 6H), 3.52-3.39 (m, 4H), 3.24-3.18 (m, 4H), 2.55-2.51 (m, 4H, obscured by DMSO peak), 1.78-1.62 (m, 2H), 1.47 (s, 18H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 167.8, 161.3, 158.3, 152.8, 122.9, 122.7 (x 2), 122.3, 122.1, 122.0, 121.9, 118.1, 117.8, 104.2, 104.0, 103.8, 103.7, 78.2, 36.1, 36.0, 35.9, 35.8, 35.5, 29.7, 28.2; IR (ATR) 3292, 2940, 1638, 1583, 1514, 1463, 1432, 1399, 1365, 1246, 1205, 1155, 1098, 1060, 998, 893, 747, 666 cm^{-1}.

*d) Preparation of 48.*

48

A solution of 4M HCl in dioxane (10 mL) was added to the bis-Boc protected octapyrrole **46** (191 mg, 0.14 mmol). The slurry was allowed to stir at room temperature under a nitrogen atmosphere for 1 h, at which point TLC (90:10 v/v $CHCl_3$/MeOH) revealed complete consumption of starting material. The solvent was removed by evaporation *in vacuo* to provide the pyrrole amine HCl salt **47** as a solid which was analysed by LC/MS (1.65 min (ES+) *m/z* (relative intensity) 1193 ($[M + H]^{+\cdot}$, 3), 1071 (2), 975 (2), 617 (10), 597 (100), 534 (4), 412 (4), 123 (35)) and carried through to the next step without further purification. In a separate vessel, EDCI (58 mg, 0.30 mmol) was added to a stirred solution of PBD-acid **12** (142 mg, 0.27 mmol) in anhydrous DMF (5 mL) at room temperature. After 5 min stirring at room temperature, the reaction mixture was treated with HOBt (41 mg, 0.30 mmol) and allowed to stir under a nitrogen atmosphere for 16 h where TLC (90:10 v/v $CHCl_3$/MeOH) revealed reaction completion. The solution containing the Bt-ester of **12** was added to the pyrrole amine HCl salt **47** in the presence of DIPEA (52 µL, 38 mg, 0.30 mmol) and the reaction mixture was allowed to stir under a nitrogen atmosphere. After 16 h stirring LC/MS (3.17 min (ES+) *m/z* (relative intensity) 1117 (51), 1098 ($[M + 2H]^{2+\cdot}$, 100), 664 (15), 628 (10), 143 (80)) and TLC (90:10 v/v $CHCl_3$/MeOH) revealed formation of the desired product. Following dilution with H_2O (300 mL), the mixture was extracted with $CHCl_3$ (2 x 50 mL). The organic layer was washed with 1% aqueous citric acid (30 mL), saturated aqueous $NaHCO_3$ (30 mL), brine (30 mL), dried ($MgSO_4$), filtered and evaporated to provide the crude product. Purification by flash chromatography (gradient elution: 98:2 v/v $CHCl_3$/MeOH to 92.5:7.5 v/v $CHCl_3$/MeOH) provided the pure bis-PBD-octapyrrole **48** as a solid (44.1 mg, 15%).

e) Preparation of dimer 49 (SJG-085).

49

A catalytic amount of tetrakis(triphenylphosphine)palladium (1.13
mg, 0.98 µmol) was added to a stirred solution of the protected
PBD dimer **48** (43.1 mg, 19.7 µmol), Ph$_3$P (0.5 mg, 1.97 µmol) and
pyrrolidine (2.93 mg, 3.43 µL, 41.3 µmol) in CH$_2$Cl$_2$ (1.5 mL). The
reaction mixture was allowed to stir under a N$_2$ atmosphere at
room temperature and the progress of reaction monitored by TLC
(90:10 v/v CHCl$_3$/MeOH), after 2.5 h the reaction was not
complete. Additional tetrakis(triphenylphosphine)palladium (1.13
mg, 0.98 µmol) and pyrrolidine (2.93 mg, 3.43 µL, 41.3 µmol) were
added and the reaction mixture stirred for a further 1 h, at
which point the reaction was deemed complete by TLC. The solvent
was evaporated under reduced pressure and the resulting residue
subjected to flash chromatography (gradient elution: 95:5 v/v
CHCl$_3$/MeOH to 90:10 v/v CHCl$_3$/MeOH) to give **49** (012-SJG-085-2) as
a white solid (25.4 mg, 71%): $[\alpha]^{24}_D$ = +209° (c = 0.0263, DMSO);
^{1}H NMR (500 MHz, DMSO-d_6) δ 9.94 (s, 2H), 9.91 (s, 4H), 9.89 (s,
2H), 8.10 (t, 2H, J = 5.6 Hz), 8.07 (t, 2H, J = 5.7 Hz), 7.79 (d,
2H, J = 4.4 Hz), 7.35 (s, 2H), 7.26-7.18 (m, 6H), 6.88-6.84 (m,
12H), 4.16-4.11 (m, 2H), 4.07-4.02 (m, 2H), 3.84 (s x 2, 12H),
3.83 (s, 6H), 3.82 (s x 2, 12H), 3.71-3.66 (m, 2H), 3.64-3.58 (m,
2H), 3.48-3.43 (m, 4H), 3.40-3.33 (m, 2H, obscured by H$_2$O peak),
3.26-3.20 (m, 4H), 2.56-2.50 (m, 4H, obscured by DMSO peak), 2.45
(t, 4H, J = 7.3 Hz), 2.33-2.19 (m, 4H), 2.05 (p, 4H, J = 6.9 Hz),
1.98-1.93 (m, 4H), 1.69 (p, 2H, J = 6.7 Hz); ^{13}C NMR (125 MHz,
DMSO-d_6) δ 168.5, 164.1, 163.0, 158.0, 149.9, 141.1, 122.4,
121.7, 119.5, 117.8, 117.6, 110.8, 109.7, 104.1, 103.8, 67.5,
55.3, 53.1, 46.1, 35.9, 35.8, 35.7, 35.6, 35.4, 31.6, 28.5, 24.4,
23.4; LC/MS 2.42 min (ES+) *m/z* (relative intensity) 912 ([*M* +
2H]$^{2+}$, 100), 621 (10), 425 (5), 377 (4), 162 (40), 143 (90).

87

**Example 13: Synthesis of dimer 55 (AT-338).**

a) Preparation of 52.

A suspension of imidazole amine 51 (1.80 g, 11.6 mmol), Boc
pyrrole acid 50 (2.78 g, 11.6 mmol), EDCI (2.90 g, 15.1 mmol),
and DMAP (280 mg, 2.29 mmol) in dry DMF (7 mL) was allowed to
stir overnight at room temperature and then for a further 6 h at
60 °C. The viscous solution was added dropwise to a stirred
mixture of ice/water (300 mL) and the resulting suspension was
allowed to stir for 30 min. The precipitate was collected by
vacuum filtration, washed with water, and dried. The methyl
ester thus obtained was dissolved in MeOH (40 mL) and treated
with an aqueous solution of NaOH (0.77 g, 19.3 mmol, 15 mL). The
mixture was stirred and heated at 60 °C for 4 h, at which point
TLC revealed completion of the reaction. The reaction mixture
was diluted with water (20 mL) and the methanol removed by
evaporation *in vacuo*. The aqueous solution was then acidified to
pH 4 with cold 1N HCl. The resulting precipitate was collected
by vacuum filtration, washed with water and dried in a desiccator
to yield 3.06 g (72 %) of 52: ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.56
(s, 1H), 9.08 (s, 1H), 7.59 (s, 1H), 7.00 (s, 1H), 6.93 (s, 1H),
3.94 (s, 3H), 3.83 (s, 3H), 1.46 (s, 9H); ^{13}C NMR (100 MHz, DMSO-
d_6) δ 160.1, 158.6, 152.8, 137.2, 132.1, 122.3, 121.9, 118.0,
114.7, 104.9, 78.2, 36.1, 35.4, 28.1; MS (ES$^+$) *m/z* (relative
intensity) 364 ([M+H]$^{+\cdot}$, 80), 320.1 (100).

b) Preparation of 53.

88

A solution of **52** (580 mg, 1.59 mmol), EDCI (367 mg, 1.91 mmol), DMAP (39 mg, 0.32 mmol) and 1,3-diaminopropane (73 µL, 0.87 mmol) in anhydrous DMF (6 mL) was allowed to stir overnight. Once reaction was complete as observed by TLC the mixture was poured into water (50 mL) with vigorous stirring. The precipitate was collected by vacuum filtration and re-dissolved in chloroform (50 mL). The crude product was absorbed onto silica gel and subjected to column chromatography (silica gel, 98:2 v/v $CHCl_3$:MeOH) to yield 400 mg (33%) of pure **53**. ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.18 (s, 2H), 9.07 (s, 2H), 8.11 (t, 2H, J = 6.05 Hz), 7.48 (s, 2H), 7.00 (s, 2H), 6.89 (s, 2H), 3.95 (s, 6H), 3.83 (s, 6H), 3.30 (q, 4H, J = 6.34 Hz), 1.60 (p, 2H, J = 6.53 Hz), 1.47 (s, 18H); ^{13}C NMR (100 MHz, DMSO-d_6) δ 158.9, 158.7, 152.8, 136.1, 133.9, 122.4, 121.9, 117.9, 114.3, 104.8, 78.2, 36.1, 35.9, 34.8, 30.7, 29.5, 28.2; MS (ES$^+$) m / z (relative intensity) 765.4 ([M+H]$^{+\cdot}$, 100).

c) *Preparation of 54.*

A suspension of **53** (350 mg, 0.457 mmol) in a solution of 4N HCl-dioxane (15 mL), was stirred for 1 h and subjected to ultrasound for 3 min. The solvent was removed by evaporation *in vacuo* to provide the pyrrole amine HCl salt as a solid, which was carried through to the next step without further purification. In a separate vessel, EDCI (180 mg, 0.94 mmol) and DMAP (160 mg, 1.31 mmol) were added to a stirred solution of the PBD acid (393 mg, 0.78 mmol) in anhydrous DMF (5 mL) at room temperature. The reaction mixture was added to the vessel containing the HCl salt and allowed to stir at room temperature over night. The reaction mixture was diluted with $CHCl_3$ (100 mL) and the organic phase was washed sequentially with water (50 mL), saturated aqueous $NaHCO_3$ (50 mL), brine (50 mL) and dried over $MgSO_4$. Excess solvent was removed under vacuum to afford a yellow oil, which was purified by flash chromatography (gradient from 0:100 to 4:96 v/v $MeOH/CHCl_3$) to yield pure **54** (170 mg, 33%) which was used immediately in the next reaction.

d) Preparation of dimer 55 (AT-338).

55 AT-338

A catalytic amount of tetrakis(triphenylphosphine)palladium (2.3 mg, 2.0 µmol) was added to a stirred solution of the protected PBD dimer **54** (153 mg, 0.1 mmol), and pyrrolidine (17.2 µL, 0.21 mmol) in $CHCl_3$ (5 mL). The reaction mixture was allowed to stir under a N_2 atmosphere at room temperature and the progress of reaction monitored by TLC. After 2 h stirring at room temperature, the reaction was deemed complete by TLC. The solvent was evaporated under reduced pressure and the resulting residue subjected to flash chromatography (gradient elution: 98:2 v/v $CHCl_3/MeOH$ to 92:8 v/v $CHCl_3/MeOH$) to yield **55** as an off white solid (78 mg, 67%): ^{1}H NMR (400 MHz, DMSO-d_6) 10.25 (s, 2H), 9.89

(s, 2H), 8.10 (t, 2H, J = 6.1 Hz), 7.79 (d, 2H, J = 4.4 Hz), 7.50 (s, 2H), 7.35 (s, 2H), 7.28 (d, 2H, J = 1.7 Hz), 6.94 (d, 2H, J = 1.8 Hz), 6.84 (s, 2H), 4.21-4.00 (m, 4H), 3.95 (s, 6H), 3.84 (s, 12H), 3.75-3.55 (m, 4H), 3.47-3.35 (m, 2H), 3.30 (m, 4H), 2.45 (t, 4H, J = 7.3 Hz), 2.32-2.20 (m, 4H), 2.05 (p, 4H, J = 6.5 Hz), 1.95 (m, 4H), 1.73 (m, 2H); MS (ES$^+$) m/z (relative intensity) 1193.6 ([M + H]$^{+\cdot}$, 100); HRMS (TOF MS ES$^+$) calcd for $C_{59}H_{68}N_{16}O_{12}$ (M+H): 1193.5276. Found: 1193.5259.

Example 14: Synthesis of dimer 62 (GDK-109).

a) Preparation of 57.

The amino compound **56** (0.2 g, 0.72 mmol; *J. Am. Chem. Soc.*, 125, 12, 2003, 3471-3485), was added to a solution of **50** (0.19 g 0.79 mmol; *J. Org. Chem.*, 66, 20, 2001, 6654-6661), EDCI (0.15 g, 0.79 mmol), and DMAP (44 mg, 0.36 mmol) in DMF (5 mL) and then stirred over night. The excess solvent was evaporated under reduced pressure and the residue was diluted with CHCl$_3$ (100 mL) and was washed sequentially with 5% aqueous citric acid (30 mL), water (30 mL), saturated aqueous NaHCO$_3$ (30 mL), brine (30 mL) and dried over MgSO$_4$. The solvents were removed under vacuum to leave a yellow oil, which was further purified by flash chromatography (50% EtOAc/Hexane) to yield compound **57** (250 mg, 69%): ^{1}H NMR (CDCl$_3$, 400 MHz): δ 8.91 (s, 1H), 8.08 (s, 1H), 7.45 (s, 1H), 7.44 (s, 1H), 6.99 (s, 1H), 6.86 (d, 1H, J = 1.96 Hz), 6.59 (s, 1H), 6.50 (s, 1H), 4.05 (s, 3H), 3.91 (s, 6H), 3.83 (s, 3H); ^{13}C NMR (CDCl$_3$, 100 MHz) δ 161.5, 158.3, 155.3, 153.3, 136.0, 133.7, 122.2, 122.0, 121.2, 120.7, 120.0, 119.1, 113.9, 108.2, 103.7, 80.3, 51.2, 36.8, 36.7, 35.7, 28.3; IR (neat): 3330, 2953, 1701, 1531, 1446, 1390, 1367, 1302, 1249, 1198, 1157, 1117, 1062, 997,

901, 775 cm^{-1}; MS (ES$^+$) m/z (relative intensity) 500 ([M + H]$^{+\cdot}$,100), 501 ([M + 2H]$^{+\cdot}$, 20).

b) Preparation of 58.

57   **58**

To a solution of ester compound **57** (0.1 g, 0.2 mmol) in dioxane (15 mL), was added 1N-NaOH (0.8 mL, 0.8 mmol) and then heated at reflux for 2 h. The reaction was monitored by TLC, and the excess solvent was removed under reduced pressure. The residue was redissolved into water and was acidified with 1N-HCl to afford a precipitate, which was collected by vacuum filtration and dried to give a brown solid **58** (91 mg, 93%): ^{1}H NMR (DMSO-d_6, 400 MHz): δ 12.15 (br s, 1H), 10.10 (s, 1H), 10.08 (s, 1H), 9.08 (s, 1H), 7.51 (s, 1H), 7.47 (d, 1H, J = 1.87 Hz), 6.98 (s, 1H), 6.94 (d, 1H), 6.85 (s, 1H), 3.97 (s, 3H), 3.83 (s, 6H), 1.45 (s, 9H); ^{13}C NMR (DMSO-d_6, 100 MHz) δ 161.8, 158.6, 155.7, 153.1, 136.0, 133.9, 122.4, 121.9, 121.7, 120.3, 119.8, 114.6, 108.6, 103.7, 77.5, 36.1, 36.0, 34.8, 28.1; IR (neat): 3299, 2960, 2359, 2338, 1668, 1590, 1553, 1407, 1365, 1244, 1164, 1121, 1064, 1033, 991. 924, 776, 668, 629 cm^{-1}; MS (ES$^+$) m/z (relative intensity) 486 ([M + H]$^{+\cdot}$,100), 487 ([M + 2H]$^{+\cdot}$, 30).

c) Preparation of 59.

**58** + **10** → **59**

A solution of compound **58** (310 mg, 0.63 mmol), EDCI (134 mg, 0.70 mmol) and HOBt (100 mg, 0.70 mmol) in anhydrous DMF (5 mL) was stirred for 2 h. A solution of the amine capping unit (**10**) (284 mg, 0.70 mmol) in anhydrous DMF (5 mL) was then added and the resulting mixture was allowed to stir overnight at RT. The excess solvent was evaporated under reduced pressure and the residue was diluted with $CHCl_3$ (200 mL) and was sequentially washed with 5% aqueous citric acid (50 mL), water (50 mL), saturated aqueous $NaHCO_3$ (50 mL), brine (50 mL) and dried over $MgSO_4$. The solvents were removed under vacuum to leave a yellow oil, which was further purified by flash chromatography (EtOAc) to yield compound **59** (340 mg, 60%): $[\alpha]^{24}_D$ = +42° (c = 0.14, $CHCl_3$); ^1H NMR ($CDCl_3$, 400 MHz): δ 8.96 (s, 1H), 8.64 (s, 1H), 7.46 (s, 1H), 7.30 (m, 1H), 7.26 (s, 1H), 7.16-7.02 (m, 2H), 6.89-6.65 (m, 3H), 6.44 (d, J = 1.65 Hz, 1H), 5.84-5.63 (m, 2H), 5.16-4.97 (m, 2H), 4.69-4.65 (m, 1H), 4.50-4.41 (m, 1H), 4.18-4.02 (m, 5H), 3.84-3.96 (m, 9H), 3.78-3.43 (m, 5H), 2.15-1.90 (m, 6H), 1.48 (s, 9H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 166.9, 162.1, 158.3, 155.6, 152.8, 149.4, 147.9, 136.2, 132.8, 131.7, 128.5, 123.7, 122.5, 121.9, 120.8, 119.0, 118.2, 116.1, 114.1, 114.0, 110.7, 104.2, 103.1, 87.0, 86.1, 83.6, 81.0, 80.1, 69.0, 66.9, 61.8, 60.1, 56.0, 51.2, 46.5, 37.9, 36.8, 36.4, 35.6, 28.6, 28.4, 22.9; IR (neat): 3314, 2948, 1702, 1633, 1599, 1528, 1463, 1434, 1405, 1366, 1274, 1242, 1202, 1162, 1107, 1056, 1015, 995, 911, 775, 729, 646 cm^{-1}; MS

(ES⁺) *m/z* (relative intensity) 873 ([*M* + H]⁺·,100), 874 ([*M* + 2H]⁺·, 50).

d) Preparation of 61.

**59**   **60**

+

61   **12**

Compound **59** (340 mg, 0.38 mmol) was suspended in a solution of 4N HCl in dioxane (5 mL) and stirred for 1 h. Following evaporation of solvent *in vacuo* the grey salt **60** was treated with anhydrous DMF (5 mL) in the presence of DIPEA (338 µL, 1.94 mmol). In a separate flask, acid capping unit **12** (221 mg, 0.42 mmol) was dissolved in anhydrous DMF (5 mL), treated with EDCI (82 mg, 0.42 mmol), and stirred for 10 min at 0°C. The reaction mixture was treated with HOBt (65.6 mg, 0.42 mmol) and stirred for 3 h and the solution containing compound **60** was added dropwise and then stirred over night. The DMF was removed *in vacuo* and residue dissolved in CHCl₃ (100 mL) and washed with 5% aqueous citric acid (50 mL), water (50 mL), saturated aqueous NaHCO₃ (50 mL), brine (50 mL) and dried over MgSO₄. The solvents were removed under vacuum to leave a yellow oil which was further purified by flash chromatography (gradient from 2% MeOH/CHCl₃) to yield compound **61** (200 mg, 39%): $[\alpha]^{23}_D$ = +35° (*c* = 0.14, CHCl₃); ¹H NMR (CDCl₃, 400 MHz) δ 9.22-9.07 (m, 1H), 8.29-8.05 (m, 2H), 7.50-7.16 (m, 10H), 7.00-6.84 (m, 2H), 6.81-6.47 (m, 4H), 6.05-5.46 (m, 6H), 5.37-4.96 (m, 6H), 4.75-4.56 (m, 4H), 4.52-4.30 (m, 2H),

94

4.29-4.02 (m, 10H), 4.00-3.35 (m, 36H), 2.73-2.50 (m, 3H), 2.34-
1.87 (m, 19H), 1.85-1.66 (m, 6H), 1.65-1.45 (m, 7H); IR (neat):
3314, 2947, 2876, 1708, 1641, 1602, 1513, 1453, 1432, 1405, 1311,
1270, 1201, 1112, 1018, 774, 729, 646 cm^{-1}.

5

e) *Preparation of dimer 62 (GDK-109)*.

61

62

Compound **61** (200 mg, 0.15 mmol), Pd(PPh$_3$)$_4$ (3.5 mg, 3 µmol) and
pyrrolidine (26 µL, 0.31 mmol) were stirred in anhydrous CHCl$_3$
10   (15 mL). Reaction completion was reached in 1 h as observed by
TLC. The solvent was removed under vacuum and the residue
purified by flash chromatography (gradient from 3:97 to 4:96
MeOH/CHCl$_3$) to afford final compound **62** as an off white solid
(130 mg, 88%): $[\alpha]^{24}_D$ = +353° (*c* = 0.13, CHCl$_3$); ^{1}H NMR (CDCl$_3$, 400
15   MHz) δ 8.93 (s, 1H), 8.69 (s, 1H), 8.60 (s, 1H), 7.68 (d, 1H, *J* =
4.45 Hz), 7.63-7.62 (m, 2H), 7.48 (s, 1H), 7.43-7.42 (m, 2H),
7.39 (d, 1H, *J* = 1.46 Hz), 7.30 (d, 1H, *J* = 1.59 Hz), 6.91-6.85
(m, 2H), 6.79 (s, 1H), 6.68 (d, 1H, *J* = 1.41 Hz), 6.22 (d, 1H, *J*
= 1.55 Hz), 4.35-4.07 (m, 4H), 4.06-3.83 (m, 15H), 3.82-3.44 (m,
20   8H), 2.63- 2.46 (m, 2H), 2.34-2.13 (m, 8H), 2.06-1.84 (m, 4H); ^{13}C
NMR (CDCl$_3$, 100 MHz) δ 169.6, 164.8, 164.6, 162.8, 162.5, 161.6,

95

158.5, 155.6, 150.6, 150.3, 147.7, 147.6, 141.0, 140.7, 136.3,
133.7, 123.8, 122.0, 121.7, 120.7, 120.5, 120.4, 118.0, 113.6,
111.6, 111.2, 110.9, 110.3, 104.0, 102.8, 68.9, 68.0, 56.1, 56.0,
53.9, 53.7, 50.8, 46.8, 46.6, 38.2, 36.8, 36.3, 35.5, 32.9, 29.5,
29.4, 28.1, 24.9, 24.1; IR (neat): 3280, 2948, 1596, 1529, 1503,
1462, 1451, 1430, 1403, 1383, 1259, 1214, 1093, 1017, 908, 874,
771, 724, 664, 645 cm^{-1}; MS (ES$^+$) m/z (relative intensity) 985([M
+ H]$^{+\cdot}$, 100), 986 ([M + 2H]$^{+\cdot}$, 60).

Example 15: Synthesis of bisulphite salt 63 (AT-361)

(16) AT-242

(63) AT-361

A solution of sodium bisulphite (12.6 mg, 0.12 mmol) in water (2
mL) was added to a stirred solution of **16** (AT-242) (72.0 mg, 60.4
µmol) in dichloromethane (2.0 mL). The reaction mixture was
allowed to stir vigorously for 5 h, after which time the organic
and aqueous layers were separated. TLC analysis (eluent-95:5 v/v
CHCl$_3$/MeOH) of the aqueous phase revealed absence of AT-242 and
presence of baseline material with strong UV absorption. The
aqueous layer was lyophilised to provide the bisulphite adduct **63**
(AT-361) as a lightweight white solid (59.2 mg, 70%): ^{1}H NMR
(CDCl$_3$, 400 MHz) δ 9.89 (m, 4H), 8.03 (t, 2H, J = 5.61 Hz), 7.19
(dd, 4H, J = 10.4, 1.67 Hz), 7.02 (s, 2H), 6.90 (m, 4H), 6.40 (s,
2H), 5.04 (s, 2H), 3.98 (m, 4H), 3.84-3.77 (m, 14H), 3.70 (s,
6H), 3.51-3.43 (m, 4H), 3.26-3.21 (m, 4H), 2.56 (m, 2H), 2.44 (t,
4H, J = 7.27 Hz), 2.11-1.60 (m, 14H); ^{13}C NMR (CDCl$_3$, 100 MHz) δ

168.8, 167.1, 161.3, 158.4, 150.8, 142.8, 140.1, 122.9, 122.7,
122.1, 122.0, 118.1, 117.8, 116.9, 112.6, 106.4, 104.1, 78.8,
67.6, 56.5, 55.8, 46.1, 36.0, 35.9, 31.9, 29.4, 22.6.

97

Example 16: Determination of DNA Cross-Linking ability and *in vitro* Cytotoxicity

(a) DNA Cross-linking

5   The extent of DNA cross-linking induced by each PBD dimer was determined using the electrophoretic assay method of Hartley, *et al.* (Hartley, J. A., Berardini, M. D., and Souhami, R. L. (1991) *Anal. Biochem. 193*, 131-134) based on the principle that, following complete denaturation of linear pBR322 DNA (~4,300 bp)

10   to the single-stranded (SS) form, an interstrand cross-link results in renaturation to double-stranded (DS) in a neutral gel.

Closed-circular DNA was linearized with HindIII, then dephosphorylated and finally 5'-singly end-labelled using $[\gamma^{32}P]$-

15   ATP and polynucleotide kinase. Reactions containing 30-40 ng of DNA and the test compound were carried out in aqueous TEOA (25 mM triethanolamine, 1mM EDTA, pH 7.2) buffer at 37°C in a final volume of 50 µl for 2 h. Reactions were terminated by addition of an equal volume of stop solution (0.6 M NaOAc, 20 mM EDTA, 100

20   µg/ml tRNA) followed by precipitation with ethanol. Following centrifugation, the supernatant was discarded and the pellet dried by lyophilization. Samples were re-suspended in 10 µl of strand separation buffer (30% DMSO, 1 mM EDTA, 0.04% bromophenol blue and 0.04% xylene cylanol) and denatured by heating to 90°C

25   for 2.5 min, followed by immersion in an ice/water bath. Control non-denatured samples were re-suspended in 10 µl of non-denaturing buffer solution (0.6% sucrose, 0.04% bromophenol blue in aqueous TAE buffer [40 mM Tris, 20 mM acetic acid, 2 mM EDTA, pH 8.1]) and loaded directly onto the gel for comparison.

30

Electrophoresis was carried out for 14-16 h at 40 V using a 0.8% submerged agarose gel (20 × 25 × 0.5 cm) in TAE buffer. Gels were dried under vacuum for 2 h at 80°C onto one layer each of Whatman 3MM and DE8I filter papers using a BioRad 583 gel dryer.

35   Autoradiographs were obtained after exposure of Hyperfilm-MP film (Amersham plc, U.K.) to the dried gel for either 4 h with a

98

screen (or over night, without a screen, to obtain a sharper image). Film bands were quantitated using a BioRad GS-670 imaging laser densitometer. Percentage cross-linking was calculated by measuring the total DNA in each lane (summed density for the

5   double-stranded [DS] and single-stranded [SS] bands) relative to the amount of cross-linked DNA (density of DS band alone). A dose-response curve was derived by plotting drug concentration against the determined percentage level of cross-linked DNA which was then analysed to determine the concentration of test compound

10   that results in 50% cross-linked plasmid DNA (XL_{50}).

(b) In vitro cytoxicity

(i) K562 cells

K562 human chronic myeloid leukaemia cells were maintained in

15   RPM1 1640 medium supplemented with 10% fetal calf serum and 2 mM glutamine at 37°C in a humidified atmosphere containing 5% CO_2 and were incubated with a specified dose of drug for 1 h at 37°C in the dark. The incubation was terminated by centrifugation (5 min, 300 g) and the cells were washed once with drug-free medium.

20   Following the appropriate drug treatment, the cells were transferred to 96-well microtiter plates (10^4 cells per well, 8 wells per sample). Plates were then kept in the dark at 37°C in a humidified atmosphere containing 5% CO_2. The assay is based on the ability of viable cells to reduce a yellow soluble

25   tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*-tetrazolium bromide (MTT, Aldrich-Sigma), to an insoluble purple formazan precipitate. Following incubation of the plates for 4 days (to allow control cells to increase in number by approximately 10 fold), 20 µL of MTT solution (5 mg/mL in

30   phosphate-buffered saline) was added to each well and the plates further incubated for 5 h. The plates were then centrifuged for 5 min at 300 g and the bulk of the medium pipetted from the cell pellet leaving 10-20 µL per well. DMSO (200 µL) was added to each well and the samples agitated to ensure complete mixing. The

35   optical density was then read at a wavelength of 550 nm on a Titertek Multiscan ELISA plate reader, and a dose-response curve was constructed. For each curve, an IC_{50} value was read as the

99

dose required to reduce the final optical density to 50% of the
control value.

(ii) NCI 60 cell screen

The National Cancer Institute (NCI), Bethesda, Maryland, USA has
available an *in vitro* cytotoxicity screen which consists of
approximately 60 human tumour cell lines against which compounds
are tested at a minimum of five concentrations each differing 10-
fold. A 48 h continuous exposure protocol is used, where cell
viability or growth is estimated with an SRB protein assay.

The test compounds were evaluated against approximately 60 human
tumour cell lines. The NCI screening procedures were described
in detail by Monks and co-workers (Monks, A *et al.*, Journal of
the National Cancer Institute, 1991, 83, 757). Briefly, cell
suspensions were diluted according to the particular cell type
and the expected target cell density (5000-40,000 cells per well
based on cell growth characteristics), and added by pipette (100
µL) into 96-well microtitre plates. The cells were allowed a
preincubation period of 24 h at 37°C for stabilisation.
Dilutions at twice the intended test concentration were added at
time zero in 100 µL aliquots to the wells. The test compounds
were evaluated at five 10-fold dilutions (10^{-4}, 10^{-5}, 10^{-6}, 10^{-7}
and 10^{-8} µM). The test compounds were incubated for 48 h in 5%
CO_2 atmosphere and 100% humidity. The cells were then assayed
using the sulphorhodamine B assay. A plate reader was used to
read the optical densities and a microcomputer processed the
readings into GI_{50} values (in Moles), which is the dosage required
to limit cell growth to 50%.

Table 1: Comparison of DNA Cross-linking and Cytotoxicity Data
for the dimers

Compound Number	XL$_{50}$ (μM)	IC$_{50}$ (μM)	GI$_{50}$ (μM)
(15) AT-281	N/A	0.34	0.01
(16) AT-242	Alkali : 0.18	2.21	0.02
(17) AT-288	N/A	0.52	0.02
(2) SJG-604	Alkali : 3.5	23.0	31.6
(1) SJG-605	Alkali : 1.3	1.20	1.00
(13) AT-217	Alkali : 0.35 Heat : 3.8	N/A	19.0
(14) AT-234	Alkali : <0.1 Heat : 0.4	25.5	0.01
(18) AT-235	Alkali : <0.1 Heat : 0.23	1.51	0.01
(55) AT-338	N/A	0.0404	0.0295
(63) AT-361	N/A	33.8	0.022

CLAIMS

1.   A compound of formula (**I**):

PBD-A-Y-X-(Het)$_{na}$-L-(Het)$_{nb}$-L-(Het)$_{nc}$-T-(Het')$_{nd}$-L-(Het')$_{ne}$-L-(Het')$_{nf}$-X'-Y'-A'-PBD'

(**I**)

and salts, solvates, chemically protected forms, and prodrugs
thereof, wherein

PBD   PBD'

with the bonds at the 8 position on each molecule bond to the A
and A' groups respectively.
the dotted lines indicate the optional presence of a double bond
between C1 and C2 or C2 and C3;
R^2 and R^3 are independently selected from -H, -OH, =O, =CH$_2$, -CN,
-R, OR, halo, =CH-R, O-SO$_2$-R, CO$_2$R and COR;
R^6, R^7 and R^9 are independently selected from H, R, OH, OR, SH,
SR, NH$_2$, NHR, NRR', nitro, Me$_3$Sn and halo; where R and R' are
independently selected from optionally substituted C$_{1-7}$ alkyl, C$_{3-20}$
heterocyclyl and C$_{5-20}$ aryl groups; or
R^6 and R^7 together form a group -O-(CH$_2$)$_p$-O-, where p is 1 or 2;
R^{10} is a nitrogen protecting group and R^{15} is either O-R^{11}, where
R^{11} is a hydroxyl protecting group; or
R^{15} is OH, =O or =S; or
R^{10} and R^{15} together form a double bond between C10 and N11;
A is selected from O, S, NH or a single bond;
Y is a divalent group such that HY = R, or a single bond;
X and X' are both either NH or C(=O);
each Het and Het' is independently an amino-heteroarylene-
carbonyl group;
each L is independently selected from β-alanine, glycine, 4-
aminobutanoic acid and a single bond;

T is a divalent linker group of the form:

-NH-Q-NH- or -C(=O)-Q-C(=O)-

wherein Q is a divalent group such that HQ = R;

A', Y', Het', $R^{2'}$, $R^{3'}$, $R^{6'}$, $R^{7'}$, $R^{9'}$, $R^{10'}$, $R^{11'}$ and $R^{15'}$ are all

independently selected from the same lists as previously defined

for A, Y, Het, R^2, R^3, R^6, R^7, R^9, R^{10}, R^{11} and R^{15} respectively;

na, nb, nc, nd, ne and nf are each independently 0 to 5 and the

sum na + nb + nc + nd + ne + nf is 0 to 16.

2.   A compound according to claim 1, wherein the sums na + nb +

nc and nd + ne + nf are equal.

3.   A compound according to either claim 1 or claim 2, wherein

Het and Het' are nitrogen containing heteroarylene units.

4.   A compound of formula (II):

PBD-A-Y-X-(Het)$_{ng}$-[L-(Het)$_{nh}$]$_{nj}$-X'-Y'-A'-PBD'

(II)

and salts, solvates, chemically protected forms, and prodrugs

thereof, wherein

PBD   PBD'

the bonds at the 8 position on PBD and PBD' bond to A and A'

groups respectively;

the dotted lines indicate the optional presence of a double bond

between C1 and C2 or C2 and C3;

R^2 and R^3 are independently selected from -H, -OH, =O, =CH$_2$, -CN,

-R, OR, halo, =CH-R, O-SO$_2$-R, CO$_2$R and COR;

R^6, R^7 and R^9 are independently selected from H, R, OH, OR, SH,

SR, NH$_2$, NHR, NRR', nitro, Me$_3$Sn and halo; where R and R' are

independently selected from optionally substituted C_{1-7} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups; or

R^6 and R^7 together form a group $-O-(CH_2)_p-O-$, where p is 1 or 2;

R^{10} is a nitrogen protecting group and R^{15} is either $O-R^{11}$, where R^{11} is a hydroxyl protecting group; or

R^{15} is OH, $=O$ or $=S$; or

R^{10} and R^{15} together form a double bond between C10 and N11;

A is selected from O, S, NH or a single bond;

Y is a divalent group such that HY = R, or a single bond;

each Het is independently an amino-heteroarylene-carbonyl group;

each L is independently selected from β-alanine, glycine, 4-aminobutanoic acid and a single bond;

A', Y', $R^{2'}$, $R^{3'}$, $R^{6'}$, $R^{7'}$, $R^{9'}$, $R^{10'}$, $R^{11'}$ and $R^{15'}$ are all independently selected from the same lists as previously defined for A, Y, Het, R^2, R^3, R^6, R^7, R^9, R^{10}, R^{11} and R^{15} respectively;

ng is 1 to 5, nh is 1 to 5 and nj is 0 to 3

X and X' are either NH and C(=O) respectively or C(=O) and NH respectively.

5.   A compound according to claim 4, wherein the total number of Het groups in the compound represented by the sum ng + (nj x nh)) is 1 to 3.

6.   A compound according to either claim 4 or claim 5, wherein Het are nitrogen containing heteroarylene units.

7.   A compound according to any one of the preceding claims, wherein PBD and PBD' are the same.

8.   A compound according to any one of the preceding claims, wherein R^9 and $R^{9'}$ are H.

9.   A compound according to any one of the preceding claims, wherein R^2, R^3, $R^{2'}$ and $R^{3'}$ are independently selected from R and H.

104

10.   A compound according to any one of the preceding claims, wherein R^6 and $R^{6'}$ are independently selected from H, OH, OR, SH, NH_2, nitro and halo.

11.   A compound according to any one of the preceding claims, wherein R^7 and $R^{7'}$ are independently selected from H, OR, SH, SR, NH_2, NHR, NRR' and halo.

12.   A compound according to any one of the preceding claims, wherein R^{10} and R^{15} together form a double bond between N10 and C11 and $R^{10'}$ and $R^{15'}$ together form a double bond between N10' and C11'.

13.   A compound according to any one of claims 1 to 11, wherein R^{10} and $R^{10'}$ are independently selected from H, BOC, Troc and alloc, and R^{11} and $R^{11'}$ are independently selected from OH, THP or a silyl oxygen protecting group.

14.   A compound according to any one of claims 1 to 13 for use in a method of therapy.

15.   A pharmaceutical composition containing a compound of any one of claims 1 to 13, and a pharmaceutically acceptable carrier or diluent.

16.   Use of a compound according to any one of claims 1 to 13 in the manufacture of a medicament for treating a proliferative disease.

17.   A method of treatment of a proliferative disease, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of any one of claims 1 to 13.

INTERNATIONAL SEARCH REPORT

PCT/GB2005/000767

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   C07D487/04   C07D519/00   A61K31/5517   A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7   C07D   A61K   A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category°	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GREGSON ET AL: "Synthesis of the first examples of A-C8/C-C2 amide-Linked pyrrolo'2,1-c!'1,4!benzodiazepine dimers" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 14, 31 May 2003 (2003-05-31), pages 2277-2280, XP002329063 the whole document	1-17
Y	KAMAL ET AL: "Synthesis and DNA-binding affinity of A-C8/C-C2 alkoxyamido-linked pyrrolo'2,1-c!'1,4!benzodiazepine dimers" BIOROGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 13, no. 22, 14 October 2003 (2003-10-14), pages 3955-3958, XP002329064 the whole document	1-17

-/--

[X] Further documents are listed in the continuation of box C.   [ ] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 May 2005	08/06/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Cortés, J

Form PCT/ISA/210 (second sheet) (January 2004)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	REDDY ET AL: "SYNTHETIC DNA MINOR GROOVE-BINDING DRUGS" PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 84, October 1999 (1999-10), pages 1-111, XP000984832 ISSN: 0163-7258 the whole document	1-17

INTERNATIONAL SEARCH REPORT

PCT/GB2005/000767

Box II   Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

   Although claim   17   is directed to a method of treatment of the
   human/animal body, the search has been carried out and based on the alleged
   effects of the compound/composition.

2. [ ] Claims Nos.:
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such
   an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III   Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all
   searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
   of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report
   covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
   restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest
[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.